

Gregory Lip

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6016108/gregory-lip-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

1,521
papers

99,604
citations

128
h-index

286
g-index

1,815
ext. papers

125,234
ext. citations

5.6
avg, IF

8.48
L-index

#	Paper	IF	Citations
1521	A Rollercoaster Plunge into 2022.. <i>Thrombosis and Haemostasis</i> , 2022 , 122, 1-4	7	1
1520	Discordance between LDL-C and Apolipoprotein B Levels and Its Association with Renal Dysfunction: Insights from a Population-Based Study.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	1
1519	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress.. <i>Biomarker Insights</i> , 2022 , 17, 11772719211066791	3.5	
1518	Outcome of Femoral Angioplasty/Stenting Procedures in Different Ethnic Groups in England: A Retrospective Analysis of Hospital Episode Statistics and Review of Literature.. <i>Journal of Endovascular Therapy</i> , 2022 , 15266028211070967	2.5	
1517	Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS): Protocol for a randomized controlled trial.. <i>International Journal of Stroke</i> , 2022 , 17474930211057722	6.3	3
1516	Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry.. <i>European Journal of Clinical Investigation</i> , 2022 , e13745	4.6	
1515	Thrombosis and Haemostasis 2021 Editors' Choice Papers.. <i>Thrombosis and Haemostasis</i> , 2022 , 122, 163-170	4.7	2
1514	Atrial high rate episodes as a marker of atrial cardiomyopathy: In the quest of the Holy Grail. Author's reply.. <i>European Journal of Internal Medicine</i> , 2022 ,	3.9	1
1513	Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation.. <i>Stroke</i> , 2022 , STROKEAHA121036757	6.7	2
1512	Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration.. <i>Circulation</i> , 2022 , 145, 392-409	16.7	4
1511	Impact of Physical Activity on All-Cause Mortality According to Specific Cardiovascular Disease.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 811058	5.4	0
1510	4S-AF scheme and ABC pathway guided management improves outcomes in atrial fibrillation patients.. <i>European Journal of Clinical Investigation</i> , 2022 , e13751	4.6	3
1509	Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention. <i>International Journal of Clinical Practice</i> , 2022 , 2022, 1-8	2.9	
1508	Kidney Function According to Different Equations in Patients Admitted to a Cardiology Unit and Impact on Outcome.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	2
1507	The Reply.. <i>American Journal of Medicine</i> , 2022 , 135, e59-e60	2.4	
1506	Breast cancer and incident cardiovascular events: A systematic analysis at the nationwide level.. <i>European Journal of Clinical Investigation</i> , 2022 , e13754	4.6	
1505	Effects of multimorbidity on incident COVID-19 events and its interplay with COVID-19 event status on subsequent incident myocardial infarction (MI).. <i>European Journal of Clinical Investigation</i> , 2022 , e13760	4.6	1

1504	Association of rhythm control with incident dementia among patients with atrial fibrillation: a nationwide population-based cohort study.. <i>Age and Ageing</i> , 2022 , 51,	3	2
1503	Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation.. <i>Clinical Research in Cardiology</i> , 2022 , 1	6.1	0
1502	MRI and CT imaging biomarkers of cerebral amyloid angiopathy in lobar intracerebral hemorrhage.. <i>International Journal of Stroke</i> , 2022 , 17474930211062478	6.3	0
1501	Design and rationale of a nationwide screening analysis from the LIPIDOGram2015 and LIPIDOGEn2015 studies.. <i>Archives of Medical Science</i> , 2022 , 18, 604-616	2.9	3
1500	Association of proteinuria and hypertension with incident atrial fibrillation in an elderly population: nationwide data from a community-based elderly cohort. <i>Journal of Hypertension</i> , 2022 , 40, 128-135	1.9	0
1499	Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation.. <i>European Heart Journal Supplements</i> , 2022 , 24, A42-A55	1.5	0
1498	Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.. <i>PLoS ONE</i> , 2022 , 17, e0264538	3.7	1
1497	Telemedical Monitoring Based on Implantable Devices-the Evolution Beyond the CardioMEMS [®] Technology.. <i>Current Heart Failure Reports</i> , 2022 , 19, 7	2.8	1
1496	Non-alcoholic Fatty Liver Disease and the Risk of Incident Atrial Fibrillation in Young Adults: A Nationwide Population-Based Cohort Study.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 832023	5.4	1
1495	Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry.. <i>Clinical Research in Cardiology</i> , 2022 , 1	6.1	0
1494	Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry.. <i>Journal of the American Heart Association</i> , 2022 , e023907 ⁶	6	0
1493	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry.. <i>European Journal of Clinical Investigation</i> , 2022 , e13773	4.6	1
1492	Impact of Multimorbidity and Polypharmacy on Clinical Outcomes of Elderly Chinese Patients with Atrial Fibrillation.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	1
1491	Thoracic aortic aneurysms and atrial fibrillation: commonality in pathophysiological pathways.. <i>Cardiovascular Research</i> , 2022 , 118, e32-e35	9.9	0
1490	Clinical risk factors for retinal artery occlusions: a nationwide case-control study.. <i>International Ophthalmology</i> , 2022 , 1	2.2	3
1489	Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke.. <i>Stroke</i> , 2022 , STROKEAHA121037316	6.7	2
1488	Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.. <i>Clinical Research in Cardiology</i> , 2022 , 1	6.1	0
1487	Left Atrial Appendage Occlusion-A Choice or a Last Resort? How to Approach the Patient.. <i>Interventional Cardiology Clinics</i> , 2022 , 11, 135-142	1.4	

1486	How to use digital devices to detect and manage arrhythmias: an EHRA practical guide.. <i>Europace</i> , 2022 ,	3.9	2
1485	Incident and recurrent myocardial infarction (MI) in relation to comorbidities: Prediction of outcomes using machine learning algorithms.. <i>European Journal of Clinical Investigation</i> , 2022 , e13777	4.6	1
1484	Low Risk of Dementia in Patients With Newly Diagnosed Atrial Fibrillation and a Clustering of Healthy Lifestyle Behaviors: A Nationwide Population-Based Cohort Study.. <i>Journal of the American Heart Association</i> , 2022 , e023739	6	0
1483	Effects of the Atrial Fibrillation Better Care Pathway on Outcomes Among Clinically Complex Chinese Patients With Atrial Fibrillation With Multimorbidity and Polypharmacy: A Report From the ChiOTEAF Registry.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024319	6	0
1482	Atrial fibrillation.. <i>Nature Reviews Disease Primers</i> , 2022 , 8, 21	51.1	5
1481	The management of anticoagulants in patients with atrial fibrillation and history of falls or risk of falls: protocol for a systematic review and meta-analysis.. <i>Systematic Reviews</i> , 2022 , 11, 63	3	0
1480	Risk of Cerebrovascular Events in Intracerebral Hemorrhage Survivors With Atrial Fibrillation: A Nationwide Cohort Study.. <i>Stroke</i> , 2022 , 101161STROKEAHA121038331	6.7	1
1479	Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial.. <i>Journal of Thrombosis and Thrombolysis</i> , 2022 , 1	5.1	
1478	A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial.. <i>EuroIntervention</i> , 2022 ,	3.1	1
1477	Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry.. <i>Clinical Research in Cardiology</i> , 2022 , 1	6.1	0
1476	Cardiovascular Disorders 2022 , 463-504		
1475	Drug Interactions Affecting Antiarrhythmic Drug Use.. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022 , 101161CIRCEP121007955	6.4	0
1474	Atrial fibrillation, a contemporary sign of multimorbidity and irregular social inequity. <i>Lancet Regional Health - Europe, The</i> , 2022 , 17, 100395		0
1473	Impact of Integrated Care Management on Clinical Outcomes in Atrial Fibrillation Patients: A Report From the FANTASIA Registry.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 856222	5.4	0
1472	Comparison Between the 24-hour Holter Test and 72-hour Single-Lead Electrocardiogram Monitoring With an Adhesive Patch-Type Device for Atrial Fibrillation Detection: Prospective Cohort Study.. <i>Journal of Medical Internet Research</i> , 2022 , 24, e37970	7.6	0
1471	Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry. <i>International Journal of Clinical Practice</i> , 2022 , 2022, 1-9	2.9	0
1470	Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy. <i>JAMA Network Open</i> , 2022 , 5, e2213945	10.4	0
1469	Frailty Prevalence and Impact on Outcomes in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of 1,187,000 Patients. <i>Ageing Research Reviews</i> , 2022 , 101652	12	3

1468	Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1107-1114	7	3
1467	Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation. <i>Annals of Neurology</i> , 2021 ,	9.4	3
1466	Newly diagnosed atrial fibrillation and hospital utilization in heart failure: a nationwide cohort study. <i>ESC Heart Failure</i> , 2021 , 8, 4808	3.7	2
1465	Catheter ablation for atrial fibrillation in heart failure: untying the Gordian knot. <i>Journal of Geriatric Cardiology</i> , 2021 , 18, 297-306	1.7	1
1464	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. <i>Rheumatology International</i> , 2021 , 1	3.6	1
1463	Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real-World Data. <i>Journal of the American Heart Association</i> , 2021 , 10, e021970	6	2
1462	Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis. <i>Journal of the American Heart Association</i> , 2021 , 10, e022628	6	0
1461	2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. <i>Journal of Arrhythmia</i> , 2021 , 37, 1389-1426	1.5	8
1460	Atrial High-Rate Episode Duration Thresholds and Thromboembolic Risk: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2021 , 10, e022487	6	3
1459	Exercise-based cardiac rehabilitation vs. percutaneous coronary intervention for chronic coronary syndrome: impact on morbidity and mortality. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	3
1458	2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. <i>Thrombosis and Haemostasis</i> , 2021 , 122,	7	16
1457	Integrated Care of Atrial Fibrillation Using the ABC (Atrial fibrillation Better Care) Pathway Improves Clinical Outcomes in Chinese Population: An Analysis From the Chinese Atrial Fibrillation Registry. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 762245	5.4	0
1456	CHA DS -VASc impact on risk following percutaneous coronary intervention in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2021 , e13717	4.6	
1455	Palpitations in the Cancer Patient.. <i>European Cardiology Review</i> , 2021 , 16, e45	3.9	1
1454	Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort. <i>Internal and Emergency Medicine</i> , 2021 , 1	3.7	4
1453	Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	7
1452	Ischemic Stroke in Patients With Hypertrophic Cardiomyopathy According to Presence or Absence of Atrial Fibrillation. <i>Stroke</i> , 2021 , STROKEAHA121034213	6.7	1
1451	Oral Anticoagulation Timing in Patients with Acute Ischaemic Stroke and Atrial Fibrillation. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	1

1450	Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Clinical Drug Investigation</i> , 2021 , 41, 941-953	3.3	0
1449	Are low doses of non-vitamin K antagonists effective in Chinese patients with atrial fibrillation? A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>International Journal of Stroke</i> , 2021 , 17474930211053140	6.3	0
1448	Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. <i>BMC Medicine</i> , 2021 , 19, 256	11.4	4
1447	Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. <i>European Heart Journal</i> , 2021 , 42,	9.5	3
1446	Response to Comment on Choi et al. Alcohol Abstinence and the Risk of Atrial Fibrillation in Patients With Newly Diagnosed Type 2 Diabetes Mellitus: a Nationwide Population-Based Study. <i>Diabetes Care</i> 2021;44:1393-1401. <i>Diabetes Care</i> , 2021 , 44, e199	14.6	
1445	Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAMe-TTR score-guided strategy in anticoagulant-naïve Thai patients with atrial fibrillation (TREATS-AF): a study protocol. <i>BMJ Open</i> , 2021 , 11, e0051007	3	1
1444	Clinical Characteristics and Outcomes of Very Elderly Patients With Atrial Fibrillation at High Bleeding Risk - The Fushimi AF Registry. <i>Circulation Reports</i> , 2021 , 3, 629-638	0.7	1
1443	Cardiovascular disease prevention: Risk factor modification at the heart of the matter. <i>The Lancet Regional Health - Western Pacific</i> , 2021 , 17, 100291	5	0
1442	Prevalence of atrial fibrillation and outcomes in older long-term care residents: a systematic review. <i>Age and Ageing</i> , 2021 , 50, 744-757	3	2
1441	Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 405-414	6.4	1
1440	Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 975-986	3.9	6
1439	Atrial fibrillation pattern and factors affecting the progression to permanent atrial fibrillation. <i>Internal and Emergency Medicine</i> , 2021 , 16, 1131-1140	3.7	8
1438	A greater burden of atrial fibrillation is associated with worse endothelial dysfunction in hypertension. <i>Journal of Human Hypertension</i> , 2021 , 35, 667-677	2.6	0
1437	Age-Dependent Anticoagulant Therapy for Atrial Fibrillation Patients with Intermediate Risk of Ischemic Stroke: A Nationwide Population-Based Study. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1151-1160	17.0	7
1436	Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 1057-1069	5.9	1
1435	Atrial Fibrillation and Stroke. <i>Cardiac Electrophysiology Clinics</i> , 2021 , 13, 243-255	1.4	0
1434	Identifying At-Risk Patients for Sustained Atrial High-Rate Episodes Using the CHEST Score: The West Birmingham Atrial Fibrillation Project. <i>Journal of the American Heart Association</i> , 2021 , 10, e017519	6	6
1433	Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	1

1432	Improving Stroke Risk Prediction in the General Population: A Comparative Assessment of Common Clinical Rules, a New Multimorbid Index, and Machine-Learning-Based Algorithms. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	11
1431	Small vessel disease burden and intracerebral haemorrhage in patients taking oral anticoagulants. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 ,	5.5	3
1430	Improving the diagnosis of heart failure in patients with atrial fibrillation. <i>Heart</i> , 2021 , 107, 902-908	5.1	3
1429	Long-term outcomes of postoperative atrial fibrillation following non cardiac surgery: A systematic review and metanalysis. <i>European Journal of Internal Medicine</i> , 2021 , 85, 27-33	3.9	5
1428	Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study. <i>Cardiovascular Diabetology</i> , 2021 , 20, 71	8.7	2
1427	Alterations in atrial electrogram amplitude as steady sinus rhythm transitions to paroxysmal atrial fibrillation during continuous monitoring in patients with implantable cardiac devices: Insights from the IMPACT study. <i>Journal of Cardiovascular Electrophysiology</i> , 2021 , 32, 1357-1363	2.7	0
1426	Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2021 , 1	6.1	6
1425	Hypertension Burden and the Risk of New-Onset Atrial Fibrillation: A Nationwide Population-Based Study. <i>Hypertension</i> , 2021 , 77, 919-928	8.5	4
1424	Nonatrial Fibrillation Patients With Complete P Wave Disappearance: An Overlooked Population With High Stroke Risk. <i>Stroke</i> , 2021 , 52, 1074-1078	6.7	2
1423	In patients with AF and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin for time to clinical events. <i>Annals of Internal Medicine</i> , 2021 , 174, JC43	8	0
1422	Longitudinal Patterns in Antithrombotic Therapy in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention in the Non-Vitamin K Oral Anticoagulant Era: A Nationwide Population-Based Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
1421	Optimizing indices of AF susceptibility and burden to evaluate AF severity, risk and outcomes. <i>Cardiovascular Research</i> , 2021 ,	9.9	16
1420	Assessment of endogenous fibrinolysis in clinical practice using novel tests: ready for clinical roll-out?. <i>SN Applied Sciences</i> , 2021 , 3, 1	1.8	
1419	Characteristics and clinical outcomes in atrial fibrillation patients classified using cluster analysis: the Fushimi AF Registry. <i>Europace</i> , 2021 , 23, 1369-1379	3.9	3
1418	Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology. <i>European Journal of Internal Medicine</i> , 2021 , 86, 1-11	3.9	12
1417	Alcohol Abstinence and the Risk of Atrial Fibrillation in Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Nationwide Population-Based Study. <i>Diabetes Care</i> , 2021 , 44, 1393-1401	14.6	8
1416	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1903-1921	15.1	84
1415	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1620-1630	27.4	235

1414	Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF. <i>PLoS ONE</i> , 2021 , 16, e0249524	3.7	3
1413	Clinical outcomes following rhythm control for atrial fibrillation: is early better?. <i>Expert Review of Cardiovascular Therapy</i> , 2021 , 19, 277-287	2.5	1
1412	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	21
1411	Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients. <i>Stroke</i> , 2021 , 52, 1225-1233	6.7	7
1410	Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. <i>Lancet Neurology</i> , 2021 , 20, 294-303	24.1	12
1409	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021 , 23, 1612-1676	3.9	99
1408	Intracerebral Hemorrhage and Exposure to Antithrombotic Drugs. <i>JAMA Network Open</i> , 2021 , 4, e219175	5.4	
1407	Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity. <i>Advances in Therapy</i> , 2021 , 38, 3166-3184	4.1	2
1406	Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , 2021 , 20, 100	8.7	20
1405	Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. <i>BMJ, The</i> , 2021 , 373, n991	5.9	12
1404	Associations between COVID-19 and 30-day thromboembolic events and mortality in people with dementia receiving antipsychotic medications. <i>Pharmacological Research</i> , 2021 , 167, 105534	10.2	1
1403	Predicting Silent Atrial Fibrillation in the Elderly: A Report from the NOMED-AF Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
1402	Incident atrial fibrillation in patients with differentiated thyroid cancer: a meta-analysis. <i>Endocrine-Related Cancer</i> , 2021 , 28, 325-335	5.7	2
1401	Adherence to the 'Atrial Fibrillation Better Care' Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-Analysis of 285,000 Patients. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	45
1400	Quality of care and risk of incident atrial fibrillation in patients with newly-diagnosed heart failure: A nationwide cohort study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 ,	4.6	1
1399	Clinical prediction of genotypes in hypertrophic cardiomyopathy: A systematic review. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13593	4.6	1
1398	The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials). <i>Clinical Cardiology</i> , 2021 , 44, 1002-1010	3.3	1
1397	Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis. <i>European Journal of Epidemiology</i> , 2021 , 36, 793-812	12.1	4

1396	Guía ESC 2020 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración de la European Association of Cardio-Thoracic Surgery (EACTS). <i>Revista Española De Cardiología</i> , 2021 , 74, 437.e1-437.e116	1.5	3
1395	Aortovascular medicine: what is it?. <i>Journal of the Royal Society of Medicine</i> , 2021 , 114, 467-469	2.3	2
1394	Improving dynamic stroke risk prediction in non-anticoagulated patients with and without atrial fibrillation: Comparing common clinical risk scores and machine learning algorithms. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 ,	4.6	10
1393	Socioeconomic inequality in oral anticoagulation therapy initiation in patients with atrial fibrillation with high risk of stroke: a register-based observational study. <i>BMJ Open</i> , 2021 , 11, e048839	3	4
1392	Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials 2021 ,		5
1391	Myocardial Strain Imaging in Resistant Hypertension. <i>Current Hypertension Reports</i> , 2021 , 23, 24	4.7	1
1390	A prospective survey of atrial fibrillation management in Iran: Baseline results of the Iranian Registry of Atrial Fibrillation (IRAF). <i>International Journal of Clinical Practice</i> , 2021 , 75, e14313	2.9	1
1389	Response to a letter by Jolobe: ARISTOPHANES subgroup analysis of frail and older patients with NVAF receiving low doses of novel oral anticoagulants. <i>Journal of Internal Medicine</i> , 2021 , 290, 221-222	10.8	
1388	Predictors of ischemic stroke for low-risk patients with atrial fibrillation: A matched case-control study. <i>Heart Rhythm</i> , 2021 , 18, 702-708	6.7	3
1387	Smoking Cessation after Diagnosis of New-Onset Atrial Fibrillation and the Risk of Stroke and Death. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
1386	How machine learning is impacting research in atrial fibrillation: implications for risk prediction and future management. <i>Cardiovascular Research</i> , 2021 , 117, 1700-1717	9.9	8
1385	Relationship between diabetes mellitus and atrial fibrillation prevalence in the Polish population: a report from the Non-invasive Monitoring for Early Detection of Atrial Fibrillation (NOMED-AF) prospective cross-sectional observational study. <i>Cardiovascular Diabetology</i> , 2021 , 20, 128	8.7	3
1384	Challenges and opportunities in improving the management of atrial fibrillation: recent research advances and their clinical translation. <i>Cardiovascular Research</i> , 2021 , 117, 1609-1611	9.9	1
1383	The Atrial Fibrillation Better Care pathway for managing atrial fibrillation: a review. <i>Europace</i> , 2021 , 23, 1511-1527	3.9	4
1382	Association between exercise habits and stroke, heart failure, and mortality in Korean patients with incident atrial fibrillation: A nationwide population-based cohort study. <i>PLoS Medicine</i> , 2021 , 18, e1003659	11.6	4
1381	Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants. <i>Cancer Medicine</i> , 2021 , 10, 4405-4414	4.8	1
1380	Hypertension and atrial fibrillation: Closing a virtuous circle. <i>PLoS Medicine</i> , 2021 , 18, e1003598	11.6	1
1379	Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes. <i>Thrombosis Research</i> , 2021 , 205, 1-7	8.2	4

1378	Oral anticoagulants in extremely-high-risk, very elderly (>90 years) patients with atrial fibrillation. <i>Heart Rhythm</i> , 2021 , 18, 871-877	6.7	3
1377	How effective is pharmacotherapy for stroke and what more is needed? A focus on atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1807-1810	4	2
1376	Associations of hypertension burden on subsequent dementia: a population-based cohort study. <i>Scientific Reports</i> , 2021 , 11, 12291	4.9	0
1375	Prevalence and Impact of Atrial Fibrillation in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	13
1374	Exercise-Based Cardiac Rehabilitation and All-Cause Mortality Among Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2021 , 10, e020804	6	4
1373	Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. <i>BMC Medicine</i> , 2021 , 19, 139	11.4	6
1372	Revisiting the dynamic risk profile of cardiovascular/non-cardiovascular multimorbidity in incident atrial fibrillation patients and five cardiovascular/non-cardiovascular outcomes: A machine-learning approach. <i>Journal of Arrhythmia</i> , 2021 , 37, 931-941	1.5	6
1371	Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. <i>European Heart Journal</i> , 2021 , 42, 4759-4768	9.5	10
1370	Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 330-339	4.6	21
1369	Exercise and the Risk of Dementia in Patients with Newly Diagnosed Atrial Fibrillation: A Nationwide Population-Based Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
1368	COVID-19 and ischemic stroke. <i>European Journal of Neurology</i> , 2021 , 28, 3826-3836	6	8
1367	Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world. <i>Journal of Arrhythmia</i> , 2021 , 37, 990-1006	1.5	4
1366	The 2020 ESC Guidelines on the Diagnosis and Management of Atrial Fibrillation. <i>Arrhythmia and Electrophysiology Review</i> , 2021 , 10, 65-67	3.2	3
1365	Hypertension control and end-stage renal disease in atrial fibrillation: a nationwide population-based cohort study. <i>Clinical Research in Cardiology</i> , 2021 , 1	6.1	
1364	Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis. <i>Heart</i> , 2021 , 107, 1630-1636	5.1	9
1363	Chronic Kidney Disease and Cerebrovascular Disease: Consensus and Guidance From a KDIGO Controversies Conference. <i>Stroke</i> , 2021 , 52, e328-e346	6.7	6
1362	Comparative effectiveness and safety of edoxaban versus warfarin in patients with atrial fibrillation: A nationwide cohort study. <i>International Journal of Stroke</i> , 2021 , 17474930211029441	6.3	1
1361	Clinical Phenotype Classification of Atrial Fibrillation Patients Using Cluster Analysis and Associations with Trial-Adjudicated Outcomes. <i>Biomedicines</i> , 2021 , 9,	4.8	3

1360	Arterial and venous thrombosis in coronavirus 2019 disease (Covid-19): relationship with mortality. <i>Internal and Emergency Medicine</i> , 2021 , 16, 1231-1237	3.7	6
1359	Should oral anticoagulants still be prescribed to patients with atrial fibrillation with a single stroke risk factor but at high bleeding risk? a nationwide cohort study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 ,	4.6	3
1358	The importance of adherence and persistence with oral anticoagulation treatment in patients with atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, f81-f83	6.4	4
1357	Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, f84-f92	6.4	2
1356	Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 68-73	6.4	4
1355	Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor-based approach. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, f3-f10	6.4	7
1354	Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 229-237	4.6	6
1353	Thromboembolism and bleeding complications in anticoagulated patients with atrial fibrillation and native aortic or mitral valvular heart disease: a descriptive nationwide cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, f101-f110	6.4	11
1352	Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation?. <i>American Journal of Medicine</i> , 2021 , 134, 67-75.e5	2.4	
1351	Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. <i>Journal of Internal Medicine</i> , 2021 , 289, 42-52	10.8	14
1350	Left ventricular thrombosis: new perspectives on an old problem. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 158-167	6.4	17
1349	Obesity and atrial fibrillation: making inroads through fat. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 59-67	6.4	8
1348	Long-term outcomes of left atrial appendage occlusion in high-risk atrial fibrillation patients: 4-year follow up data. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 1090-1093	5.1	1
1347	Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey. <i>Annals of Medicine</i> , 2021 , 53, 17-25	1.5	6
1346	Heart rate variability in patients with atrial fibrillation and hypertension. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13361	4.6	5
1345	Optimization of atrial fibrillation care: management strategies and quality measures. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 121-133	4.6	0
1344	Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. <i>Europace</i> , 2021 , 23, 174-183	3.9	28
1343	Acute ischemic stroke management: concepts and controversies.A narrative review. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 65-79	4.3	6

1342	Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation. <i>Europace</i> , 2021 , 23, 184-195	3.9	7
1341	Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIA registry. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13431	4.6	2
1340	Atrial fibrillation and cardiac arrhythmia associated with acute dental infection: A systematic literature review and case report. <i>International Journal of Clinical Practice</i> , 2021 , 75, e13875	2.9	1
1339	Associations of atrial fibrillation progression with clinical risk factors and clinical prognosis: A report from the Chinese Atrial Fibrillation Registry study. <i>Journal of Cardiovascular Electrophysiology</i> , 2021 , 32, 333-341	2.7	1
1338	Outcomes in VKA-treated patients with atrial fibrillation and chronic kidney disease: Clinical trials vs 'real-world'. <i>International Journal of Clinical Practice</i> , 2021 , 75, e13888	2.9	1
1337	Pathophysiological insights into atrial fibrillation: revisiting the electrophysiological substrate, anatomical substrate, and possible insights from proteomics. <i>Cardiovascular Research</i> , 2021 , 117, e41-e45	4.9	1
1336	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 422-432	7	47
1335	The interpretation of CHA2DS2-VASc score components in clinical practice: a joint survey by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, the EHRA Young Electrophysiologists, the Association of Cardiovascular Nursing and Allied Professionals, and the European Society of Cardiology Council on Stroke. <i>Europace</i> , 2021 , 23, 314-322	3.9	3
1334	Small Vessel Disease and Ischemic Stroke Risk During Anticoagulation for Atrial Fibrillation After Cerebral Ischemia. <i>Stroke</i> , 2021 , 52, 91-99	6.7	10
1333	Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults 18-60 years with COVID-19. <i>Journal of Arrhythmia</i> , 2021 , 37, 231-237	1.5	11
1332	Peripheral Arterial Disease in Patients with Atrial Fibrillation: The AFFIRM Study. <i>American Journal of Medicine</i> , 2021 , 134, 514-518	2.4	8
1331	Vascular disease in patients with atrial fibrillation. A report from Polish participants in the EORP-AF General Long-Term Registry. <i>International Journal of Clinical Practice</i> , 2021 , 75, e13701	2.9	1
1330	Embolic Stroke of Undetermined Source: The Need for an Integrated and Holistic Approach to Care. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 251-254	7	0
1329	End-Stage renal disease and 30-day mortality for adults with and without COVID-19. <i>European Journal of Internal Medicine</i> , 2021 , 83, 93-95	3.9	1
1328	Real-World Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in a Developing Country. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1282-1292	6.1	6
1327	Long-term clinical outcomes after major bleeding in patients with atrial fibrillation: the Fushimi AF registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 163-171	4.6	1
1326	Stroke prevention strategies in high-risk patients with atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2021 , 18, 276-290	14.8	19
1325	Compliance of atrial fibrillation treatment with the ABC pathway in patients with concomitant diabetes mellitus in the Middle East based on the Gulf SAFE registry. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13385	4.6	3

1324	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. <i>European Heart Journal</i> , 2021 , 42, 373-498	9.5	1676
1323	Quality indicators for the care and outcomes of adults with atrial fibrillation. <i>Europace</i> , 2021 , 23, 494-495	5.9	23
1322	Pathophysiology of atrial fibrillation and chronic kidney disease. <i>Cardiovascular Research</i> , 2021 , 117, 1046-1059	15	
1321	The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 270-278	7	45
1320	Prescriber compliance to direct oral anticoagulant labels and impact on outcomes in Thailand. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1390-1400	3.8	0
1319	Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 31-39	6.4	3
1318	Non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation patients with concomitant peripheral artery disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 50-58	6.4	10
1317	Higher Mortality of Ischaemic Stroke Patients Hospitalized with COVID-19 Compared to Historical Controls. <i>Cerebrovascular Diseases</i> , 2021 , 50, 326-331	3.2	7
1316	Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF. <i>TH Open</i> , 2021 , 5, e35-e42	2.7	0
1315	Cardiac rehabilitation and all-cause mortality in patients with heart failure: a retrospective cohort study. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	7
1314	Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 415-423	6.4	10
1313	Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials. <i>Europace</i> , 2021 ,	3.9	4
1312	Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, f11-f19	6.4	10
1311	Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis. <i>Cardiovascular Diabetology</i> , 2021 , 20, 24	8.7	7
1310	Thoracoscopic Left Atrial Appendage Excision Plus Ablation for Atrial Fibrillation to Prevent Stroke. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2021 , 33, 61-67	1.7	2
1309	Current trends in the use of anticoagulant pharmacotherapy in the United Kingdom are changes on the horizon?. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1061-1070	4	3
1308	Thrombosis and Haemostasis 2020 Editors' Choice Papers. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 109-114	14	4
1307	Looking Back on 2020, Looking Forward to 2021. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1-3	7	3

1306	Non-Vitamin K Antagonist Oral Anticoagulants in Elderly (85 years) Patients With Newly Diagnosed Atrial Fibrillation: Changing Clinical Practice and Outcomes for Stroke Prevention in a Nationwide Cohort Study. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 52-65	6.4	9
1305	Symptom management strategies: Rhythm vs rate control in patients with atrial fibrillation in the Balkan region: Data from the BALKAN-AF survey. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14038	2.8	1
1304	Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
1303	Prevalence/incidence of atrial fibrillation based on integrated medical/pharmacy claims, and association with co-morbidity profiles/multi-morbidity in a large US adult cohort. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14042	2.9	3
1302	Cerebral Small Vessel Disease and Functional Outcome Prediction After Intracerebral Hemorrhage. <i>Neurology</i> , 2021 , 96, e1954-e1965	6.5	3
1301	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Prior Gastrointestinal Bleeding. <i>Stroke</i> , 2021 , 52, 511-520	6.7	5
1300	The impact of atrial fibrillation and long-term oral anticoagulant use on all-cause and cardiovascular mortality: A 12-year evaluation of the prospective Brazilian Study of Stroke Mortality and Morbidity. <i>International Journal of Stroke</i> , 2021 , 1747493021995592	6.3	0
1299	Prediction of thromboembolic events and mortality by the CHADS2 and the CHA2DS2-VASc in COVID-19. <i>Europace</i> , 2021 , 23, 937-947	3.9	5
1298	Should we make the risk stratification process more complex in patients with atrial fibrillation?. <i>Europace</i> , 2021 , 23, 978	3.9	1
1297	Body Mass Index and Clinical Outcomes in Asian Patients With Atrial Fibrillation Receiving Oral Anticoagulation. <i>Stroke</i> , 2021 , 52, 521-530	6.7	8
1296	Relationship Between Body Mass Index and Incidence of Atrial Fibrillation in Young Japanese Men - The Nishimura Health Survey. <i>Circulation Journal</i> , 2021 , 85, 243-251	2.9	1
1295	Endothelial dysfunction and vascular maladaptation in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13477	4.6	3
1294	Nonalcoholic fatty liver disease and the risk of atrial fibrillation stratified by body mass index: a nationwide population-based study. <i>Scientific Reports</i> , 2021 , 11, 3737	4.9	7
1293	Integrated care and outcomes in patients with atrial fibrillation and comorbidities. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13498	4.6	8
1292	Fat, Sugar or Gut Microbiota in Reducing Cardiometabolic Risk: Does Diet Type Really Matter?. <i>Nutrients</i> , 2021 , 13,	6.7	1
1291	Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study. <i>Cancer</i> , 2021 , 127, 2122-2129	6.4	8
1290	Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID-19 patients: A multicenter retrospective study. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 1038-1048	15.4	19
1289	Epidemiology of Atrial Fibrillation: Geographic/Ecological Risk Factors, Age, Sex, Genetics. <i>Cardiac Electrophysiology Clinics</i> , 2021 , 13, 1-23	1.4	12

1288	The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. <i>European Journal of Internal Medicine</i> , 2021 , 85, 80-85	3.9	6
1287	Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs. clinical-trial evidence. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	2
1286	Exercise rehabilitation associates with lower mortality and hospitalisation in cardiovascular disease patients with COVID-19. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	2
1285	Relationship between Chronic Kidney Disease, Time-in-Therapeutic Range, and Adverse Outcomes in Atrial Fibrillation: A post hoc Analysis from the AMADEUS Trial. <i>Cerebrovascular Diseases</i> , 2021 , 1-7	3.2	
1284	Clinical outcomes with digoxin vs. beta-blocker for heart rate control in permanent atrial fibrillation with heart failure. <i>European Journal of Heart Failure</i> , 2021 , 23, 1563-1565	12.3	1
1283	A new index to predict quality of anticoagulation control in patients on vitamin K antagonists: the DAFNE score. <i>Future Cardiology</i> , 2021 , 17, 685-692	1.3	
1282	Comparison among random forest, logistic regression, and existing clinical risk scores for predicting outcomes in patients with atrial fibrillation: A report from the J-RHYTHM registry. <i>Clinical Cardiology</i> , 2021 , 44, 1305-1315	3.3	4
1281	'Rise of the machines': the next frontier in individualized medicine. <i>Cardiovascular Research</i> , 2021 , 117, e129-e131	9.9	1
1280	Atrial Fibrillation in Patients with Chronic Kidney Disease. <i>Cardiology Clinics</i> , 2021 , 39, 435-446	2.5	1
1279	Mortality associated with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban. <i>Cancer Medicine</i> , 2021 , 10, 7079-7088	4.8	1
1278	Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment. <i>PLoS Medicine</i> , 2021 , 18, e1003730	11.6	2
1277	Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronization devices. <i>Europace</i> , 2021 ,	3.9	1
1276	Quality indicators in the management of elderly Chinese patients with atrial fibrillation: A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 ,	4.6	2
1275	Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding. <i>JAMA Network Open</i> , 2021 , 4, e2120064	10.4	5
1274	DOAC discontinuation among patients with atrial fibrillation according to gender and cohabitation status; A Nationwide Cohort Study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	1
1273	Poor adherence to guideline-directed anticoagulation in elderly Chinese patients with atrial fibrillation. A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> ,	4.6	4
1272	INTERASPIRE: an International Survey of Coronary Patients; Their Cardiometabolic, Renal and Biomarker Status; and the Quality of Preventive Care Delivered in All WHO Regions : In Partnership with the World Heart Federation, European Society of Cardiology, Asia Pacific Society of Cardiology, InterAmerican Society of Cardiology, and PanAfrican Society of Cardiology. <i>Current Effect of Training on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction</i> . <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 770-771	4.2	
1271		27.4	0

1270	Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. <i>Clinical Research in Cardiology</i> , 2021 , 1	6.1	4
1269	Targeted atrial fibrillation detection in COVID-19 vaccination clinics. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 526-528	4.6	3
1268	Disparities in atrial fibrillation: a call for holistic care. <i>Lancet Regional Health - Europe, The</i> , 2021 , 7, 100160		0
1267	Glucose-lowering drug use and new-onset atrial fibrillation in patients with diabetes mellitus. <i>Diabetologia</i> , 2021 , 64, 2602-2605	10.3	3
1266	Integrated Care Systems and the Aortovascular Hub. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	6
1265	Photoplethysmography rhythm interpretation: an essential skill in an era of novel technologies. <i>European Heart Journal Digital Health</i> , 2021 , 2, 361-362	2.3	0
1264	Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry. <i>Europace</i> , 2021 ,	3.9	1
1263	One-year Follow-up Results of the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>Journal of Arrhythmia</i> , 2021 , 37, 1227-1239	1.5	2
1262	Association of proteinuria and incident atrial fibrillation in patients with diabetes mellitus: a population-based senior cohort study. <i>Scientific Reports</i> , 2021 , 11, 17013	4.9	0
1261	Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. <i>European Heart Journal</i> , 2021 , 42, 3541-3554	9.5	7
1260	Impact of abdominal obesity on outcomes of catheter ablation in Korean patients with atrial fibrillation. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14696	2.9	0
1259	Updating a simple clinical score predicting incident atrial fibrillation: The CHEST score or more (mCHEST)?. <i>European Journal of Internal Medicine</i> , 2021 , 90, 27-29	3.9	1
1258	Metabolically healthy obesity and cardiovascular events: A nationwide cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2492-2501	6.7	4
1257	Association Between Change in Metabolic Syndrome Status and Risk of Incident Atrial Fibrillation: A Nationwide Population-Based Study. <i>Journal of the American Heart Association</i> , 2021 , 10, e020901	6	0
1256	"Novel Clinical Concepts in Thrombosis": Integrated Care for Stroke Management-Easy as ABC. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	7
1255	Comparing Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation: A Systematic Review and Meta-Analysis of 81,462 Patients. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
1254	Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study. <i>European Journal of Internal Medicine</i> , 2021 , 91, 75-80	3.9	
1253	Beyond atrial fibrillation detection: how digital tools impact the care of patients with atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2021 , 93, 117-118	3.9	0

1252	Comparison of HAS-BLED and ORBIT Bleeding Risk Scores in AF Patients treated with NOACs: A Report from the ESC-EHRA EORP-AF General Long-Term Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 ,	4.6	5
1251	Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13679	4.6	16
1250	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 3080-3089	15.4	3
1249	Management of cardiovascular complications of bruton tyrosine kinase inhibitors. <i>British Journal of Haematology</i> , 2021 ,	4.5	4
1248	Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. <i>Journal of the American Heart Association</i> , 2021 , 10, e021467	6	2
1247	Increased risk of ischemic stroke and systemic embolism in hyperthyroidism-related atrial fibrillation: A nationwide cohort study. <i>American Heart Journal</i> , 2021 , 242, 123-131	4.9	1
1246	Incident atrial fibrillation and its risk prediction in patients developing COVID-19: A machine learning based algorithm approach. <i>European Journal of Internal Medicine</i> , 2021 , 91, 53-58	3.9	6
1245	Risk stratification of cardiac arrhythmias and sudden cardiac death in type 2 diabetes mellitus patients receiving insulin therapy: A population-based cohort study. <i>Clinical Cardiology</i> , 2021 , 44, 1602-1612	3.3	2
1244	Comparing Warfarin and 4 Direct Oral Anticoagulants for the Risk of Dementia in Patients With Atrial Fibrillation. <i>Stroke</i> , 2021 , 52, 3459-3468	6.7	5
1243	Mobile health solutions for atrial fibrillation detection and management: a systematic review. <i>Clinical Research in Cardiology</i> , 2021 , 1	6.1	4
1242	Oral anticoagulation improves survival in very elderly Chinese patients with atrial fibrillation: A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>International Journal of Stroke</i> , 2021 , 17474930211046743	6.3	1
1241	Biomarkers for Atrial Fibrillation Detection After Stroke: Systematic Review and Meta-analysis. <i>Neurology</i> , 2021 , 97, e1775-e1789	6.5	5
1240	Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases. <i>Cardiovascular Diabetology</i> , 2021 , 20, 176	8.7	5
1239	Risk of Atrial Fibrillation in Young Adults With Isolated Diastolic, Isolated Systolic, and Systolic-Diastolic Hypertension. <i>Hypertension</i> , 2021 , 78, 1248-1258	8.5	0
1238	Relationship between multimorbidity and outcomes in atrial fibrillation. <i>Experimental Gerontology</i> , 2021 , 153, 111482	4.5	4
1237	Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2021 , 92, 100-106	3.9	7
1236	Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study. <i>Stroke</i> , 2021 , 52, 3132-3141	6.7	3
1235	Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. <i>Lancet Neurology</i> , 2021 , 20, 842-853	24.1	9

1234	Antithrombotic therapy in chronic liver disease: to clot or not to clot. <i>Lancet Regional Health - Europe, The</i> , 2021 , 10, 100226		
1233	Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Korean Circulation Journal</i> , 2021 , 51, 409-422	2.2	6
1232	Association of Exercise-Based Cardiac Rehabilitation with Progression of Paroxysmal to Sustained Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
1231	Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 1756284821997352	4.7	3
1230	Prediction of ischemic stroke in different populations: a comparison of absolute stroke risk and CHADS-VASc in real-world and clinical trial patients.. <i>European Journal of Internal Medicine</i> , 2021 ,	3.9	1
1229	Comparative Effectiveness of Early Rhythm Control Versus Rate Control for Cardiovascular Outcomes in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2021 , e023055	6	3
1228	Cardiovascular considerations in management of patients with Turner syndrome.. <i>Trends in Cardiovascular Medicine</i> , 2021 ,	6.9	1
1227	Safety and efficacy of direct oral anticoagulants (DOAC) in patients with anaemia and atrial fibrillation: an observational nation-wide Danish cohort study.. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 ,	4.6	1
1226	Associations of anemia with death and major bleeding in patients with atrial fibrillation: A report from the Chinese Atrial Fibrillation Registry Study.. <i>Clinical Cardiology</i> , 2021 ,	3.3	2
1225	Differential Presentations of Arterial Thromboembolic Events Between Venous Thromboembolism and Atrial Fibrillation Patients.. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 775564	5.4	0
1224	Photoplethysmography-Based Machine Learning Approaches for Atrial Fibrillation Prediction. <i>JACC Asia</i> , 2021 , 1, 399-408		2
1223	The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity: The mAFA-II Randomized Clinical Trial.. <i>JAMA Network Open</i> , 2021 , 4, e2140071	10.4	4
1222	Feasibility of weight loss in obese atrial fibrillation patients attending a specialist arrhythmia clinic and its impact on ablation outcomes. <i>Journal of Arrhythmia</i> , 2020 , 36, 984-990	1.5	3
1221	Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 2360-2369	6.4	3
1220	Mobile health technology facilitates population screening and integrated care management in patients with atrial fibrillation. <i>European Heart Journal</i> , 2020 , 41, 1617-1619	9.5	2
1219	Influence of BMI and geographical region on prescription of oral anticoagulants in newly diagnosed atrial fibrillation: The GLORIA-AF Registry Program. <i>European Journal of Internal Medicine</i> , 2020 , 80, 35-44	3.9	5
1218	Temporal Trends of Emergency Department Visits of Patients with Atrial Fibrillation: A Nationwide Population-Based Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
1217	Population-Based Screening or Targeted Screening Based on Initial Clinical Risk Assessment for Atrial Fibrillation: A Report from the Huawei Heart Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	9

1216	Excessive Supraventricular Ectopic Activity and Adverse Cardiovascular Outcomes: a Systematic Review and Meta-analysis. <i>Current Atherosclerosis Reports</i> , 2020 , 22, 14	6	4
1215	Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 2455-2463	3.8	14
1214	Adherence to Anticoagulant Guideline for Atrial Fibrillation Improves Outcomes in Asian Population: The COOL-AF Registry. <i>Stroke</i> , 2020 , 51, 1772-1780	6.7	10
1213	Comparison of Dabigatran Plus a P2Y Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. <i>American Journal of Medicine</i> , 2020 , 133, 1302-1312	2.4	1
1212	Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage. <i>JAMA Network Open</i> , 2020 , 3, e206424	10.4	14
1211	Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation: An Instrumental Variable Analysis of a Nationwide Cohort. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006058	5.8	10
1210	Letter by Guo et al Regarding Article, "SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation". <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006635	5.8	
1209	Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants. <i>Cardiovascular Diabetology</i> , 2020 , 19, 63	8.7	17
1208	Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression. <i>European Journal of Internal Medicine</i> , 2020 , 79, 31-36	3.9	6
1207	Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e014932	6	36
1206	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1004-1024	7	147
1205	Compliance of Atrial Fibrillation Treatment with the Atrial Fibrillation Better Care (ABC) Pathway Improves the Clinical Outcomes in the Middle East Population: A Report from the Gulf Survey of Atrial Fibrillation Events (SAFE) Registry. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
1204	Haptoglobin genotype and outcome after spontaneous intracerebral haemorrhage. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 298-304	5.5	3
1203	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <i>Europace</i> , 2020 , 22, 1147-1148	3.9	25
1202	Impact of atrial fibrillation in critically ill patients admitted to a stepdown unit. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13317	4.6	6
1201	High variability in bodyweight is associated with an increased risk of atrial fibrillation in patients with type 2 diabetes mellitus: a nationwide cohort study. <i>Cardiovascular Diabetology</i> , 2020 , 19, 78	8.7	12
1200	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <i>Journal of Arrhythmia</i> , 2020 , 36, 553-607	1.5	11
1199	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <i>Heart Rhythm</i> , 2020 , 17, e210-e216	6.7	7

1198	Risks and outcomes of gastrointestinal malignancies in anticoagulated atrial fibrillation patients experiencing gastrointestinal bleeding: A nationwide cohort study. <i>Heart Rhythm</i> , 2020 , 17, 1745-1751	6.7	6
1197	Thromboembolic and bleeding outcomes in patients with atrial fibrillation and valvular heart disease: A descriptive nationwide cohort study. <i>International Journal of Clinical Practice</i> , 2020 , 74, e13589	3.9	3
1196	Effectiveness and Safety of Oral Anticoagulants among NVAf Patients with Obesity: Insights from the ARISTOPHANES Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	12
1195	Application of the simple atrial fibrillation better care pathway for integrated care management in frail patients with atrial fibrillation: A nationwide cohort study. <i>Journal of Arrhythmia</i> , 2020 , 36, 668-677	1.5	13
1194	Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020 , 9, e014177	6	30
1193	The number needed to treat for net effect (NNTnet) as a metric for measuring combined benefits and harms. <i>Journal of Clinical Epidemiology</i> , 2020 , 125, 100-107	5.7	10
1192	Relationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: real-world data from the FANTASIA Registry. <i>Annals of Medicine</i> , 2020 , 52, 300-309	1.5	3
1191	Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA-AF registry. <i>Journal of Arrhythmia</i> , 2020 , 36, 408-416	1.5	5
1190	Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1200-1207	7	23
1189	The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20 years. <i>Internal and Emergency Medicine</i> , 2020 , 15, 1183-1192	3.7	16
1188	Current and emerging drug treatment strategies for peripheral arterial disease. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1603-1616	4	4
1187	Longer term stroke risk in intracerebral haemorrhage survivors. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 840-845	5.5	6
1186	The Effect of Integrated Care Management on Dementia in Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	12
1185	Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	12
1184	Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. <i>Drugs</i> , 2020 , 80, 995-1005	12.1	2
1183	Wearable cardioverter-defibrillator in patients at risk of sudden cardiac death: consensus document from Kalarus et al. contradicts current guideline recommendations-Authors' reply. <i>Europace</i> , 2020 , 22, 1442-1443	3.9	
1182	Effectiveness and Safety of Direct Oral Anticoagulants in Relation to Temporal Changes in Their Use. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e005894	5.8	5
1181	Blood Pressure Control and Dementia Risk in Midlife Patients With Atrial Fibrillation. <i>Hypertension</i> , 2020 , 75, 1296-1304	8.5	13

1180	Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13221	4.6	0
1179	Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 357-365	5.1	3
1178	Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1374-1380	6.1	2
1177	Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
1176	Characteristics and 2-year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA-AF. <i>ESC Heart Failure</i> , 2020 , 7, 2679-2689	3.7	1
1175	Usefulness of the NULL-PLEASE Score to Predict Survival in Out-of-Hospital Cardiac Arrest. <i>American Journal of Medicine</i> , 2020 , 133, 1328-1335	2.4	3
1174	Clinical outcomes associated with kidney function changes in anticoagulated atrial fibrillation patients: An ancillary analysis from the BOREALIS trial. <i>Journal of Arrhythmia</i> , 2020 , 36, 282-288	1.5	2
1173	Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies. <i>Frontiers in Medicine</i> , 2020 , 7, 54	4.9	9
1172	Determinants of low-quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study. <i>British Journal of Haematology</i> , 2020 , 190, 588-593	4.5	6
1171	Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. <i>Europace</i> , 2020 , 22, 496-505	3.9	13
1170	Atrial fibrillation in acute heart failure: A position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 348-357	4.3	16
1169	Algorithm for the management of antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: an updated proposal based on efficacy considerations. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 197-198	6.4	7
1168	A Toast to the Last Decade and a Very Happy 2020 from Thrombosis and Haemostasis!. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1-4	7	2
1167	Association of relative wall thickness of left ventricle with incidence of thromboembolism in patients with non-valvular atrial fibrillation: The Fushimi AF Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 273-283	4.6	5
1166	Stroke prevention in elderly patients with non-valvular atrial fibrillation in the BALKAN-AF survey. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13200	4.6	2
1165	Thrombosis and Haemostasis 2019 Editor's Choice Papers. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 184-190	4.9	3
1164	Incident Comorbidities, Aging and the Risk of Stroke in 608,108 Patients with Atrial Fibrillation: A Nationwide Analysis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	15
1163	Incidence and prognostic factors for recurrence of intracerebral hemorrhage in patients with and without atrial fibrillation: A cohort study. <i>Thrombosis Research</i> , 2020 , 191, 1-8	8.2	6

1162	Lifestyle and risk factor modification for reduction of atrial fibrillation: We could do more. <i>Trends in Cardiovascular Medicine</i> , 2020 , 30, 387-388	6.9	0
1161	Wearable cardioverter-defibrillator to reduce the transient risk of sudden cardiac death in coronary artery disease: Authors' reply. <i>Europace</i> , 2020 , 22, 1600-1601	3.9	
1160	Considerations when choosing an appropriate bleeding risk assessment tool for patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 788-790	15.4	3
1159	Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function. <i>JAMA Network Open</i> , 2020 , 3, e203593	10.4	16
1158	Clinical factors related to successful or unsuccessful cardioversion in the Edoxaban versus warfarin in subjects Undergoing cardioversion of Atrial Fibrillation (ENSURE-AF) randomized trial. <i>Journal of Arrhythmia</i> , 2020 , 36, 430-438	1.5	2
1157	Etiologic Workup in Cases of Cryptogenic Stroke: A Systematic Review of International Clinical Practice Guidelines. <i>Stroke</i> , 2020 , 51, 1419-1427	6.7	13
1156	Assessment of Arterial Stiffness in Patients With Resistant Hypertension: Additional Insights Into the Pathophysiology of This Condition?. <i>American Journal of Hypertension</i> , 2020 , 33, 107-115	2.3	5
1155	Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme. <i>Europace</i> , 2020 , 22, 47-57	3.9	9
1154	Screening for Atrial Fibrillation: Improving Efficiency of Manual Review of Handheld Electrocardiograms. <i>Engineering Proceedings</i> , 2020 , 2, 78	0.5	0
1153	Outcomes in relation to antithrombotic therapy among patients with atrial fibrillation after percutaneous coronary intervention. <i>PLoS ONE</i> , 2020 , 15, e0240161	3.7	1
1152	Towards Assigning Diagnosis Codes Using Medication History. <i>Lecture Notes in Computer Science</i> , 2020 , 203-213	0.9	1
1151	Direct Oral Anticoagulants in Atrial Fibrillation Patients With Concomitant Hyperthyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	2
1150	Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020 , 7, 1-42	1.7	0
1149	Screening for Atrial Fibrillation: Improving Efficiency of Manual Review of Handheld Electrocardiograms. <i>Engineering Proceedings</i> , 2020 , 2, 78	0.5	
1148	Optimal INR level in elderly and non-elderly patients with atrial fibrillation receiving warfarin: a report from the COOL-AF nationwide registry in Thailand. <i>Journal of Geriatric Cardiology</i> , 2020 , 17, 612-620	1.7	
1147	Adherence to the ABC (Atrial fibrillation Better Care) pathway in the Balkan region: the BALKAN-AF survey. <i>Polish Archives of Internal Medicine</i> , 2020 , 130, 187-195	1.9	8
1146	Atrial fibrillation is more frequently associated with nonobstructive coronary lesions: the Bialystok Coronary Project. <i>Polish Archives of Internal Medicine</i> , 2020 , 130, 1029-1036	1.9	2
1145	Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation. <i>Korean Circulation Journal</i> , 2020 , 50, 267-277	2.2	8

1144	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. <i>EuroIntervention</i> , 2020 , 15, 1133-1180	3.1	82
1143	The year in cardiology: arrhythmias and pacing?The year in cardiology 2019. <i>Cardiologia Croatica</i> , 2020 , 15, 132-145	0	
1142	Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and / or undergoing percutaneous coronary intervention. <i>Kardiologia Polska</i> , 2020 , 78, 512-519	0.9	1
1141	Clinical performance of the atrial fibrillation in the Russian population depending on the antithrombotic therapy: findings from the GLORIA-AF registry phase 2. <i>Russian Journal of Cardiology</i> , 2020 , 25, 4179	1.3	
1140	Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial. <i>American Journal of Medicine</i> , 2020 , 133, 1195-1202.e2	2.4	44
1139	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study. <i>Atherosclerosis Supplements</i> , 2020 , 42, e15-e24	1.7	7
1138	Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. <i>Thrombosis Research</i> , 2020 , 196, 382-394	8.2	43
1137	Atrial Fibrillation in the United Kingdom: Predicting Costs of an Emerging Epidemic Recognising and Forecasting the Cost Drivers of Atrial Fibrillation-related costs. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 ,	4.6	30
1136	Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation. <i>European Heart Journal Supplements</i> , 2020 , 22, 113-121	1.5	8
1135	Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal. <i>European Heart Journal Supplements</i> , 2020 , 22, O14-O27	1.5	5
1134	Stroke prevention in atrial fibrillation: comparison of recent international guidelines. <i>European Heart Journal Supplements</i> , 2020 , 22, O53-O60	1.5	5
1133	Atrial fibrillation in low- and middle-income countries: a narrative review. <i>European Heart Journal Supplements</i> , 2020 , 22, O61-O77	1.5	3
1132	Validation of the modified Microlife blood pressure monitor in patients with paroxysmal atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2020 , 109, 802-809	6.1	0
1131	Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry. <i>American Journal of Cardiology</i> , 2020 , 125, 383-391	3	10
1130	Evaluation of the CHEST Risk Score as a Possible Opportunistic Screening Tool for Incident Atrial Fibrillation in a Healthy Population (From a Nationwide Danish Cohort Study). <i>American Journal of Cardiology</i> , 2020 , 125, 48-54	3	12
1129	Galectin-3 and risk of atrial fibrillation: A systematic review and meta-analysis. <i>Journal of Clinical Laboratory Analysis</i> , 2020 , 34, e23104	3	11
1128	Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1018-1024	6.1	2
1127	Endothelial function in patients with atrial fibrillation. <i>Annals of Medicine</i> , 2020 , 52, 1-11	1.5	11

1126	Cognitive Impairment Before Atrial Fibrillation-Related Ischemic Events: Neuroimaging and Prognostic Associations. <i>Journal of the American Heart Association</i> , 2020 , 9, e014537	6	5
1125	Management of patients with newly-diagnosed atrial fibrillation: Insights from the BALKAN-AF survey. <i>IJC Heart and Vasculature</i> , 2020 , 26, 100461	2.4	1
1124	Blood Pressure Variability and Incidence of New-Onset Atrial Fibrillation: A Nationwide Population-Based Study. <i>Hypertension</i> , 2020 , 75, 309-315	8.5	18
1123	'Real-world' observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). <i>Europace</i> , 2020 , 22, 831-832	3.9	14
1122	The year in cardiology: arrhythmias and pacing. <i>European Heart Journal</i> , 2020 , 41, 619-625c	9.5	2
1121	Comparison of the Effect of Age (American Journal of Cardiology, 2020 , 125, 735-743	3	9
1120	Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study. <i>Chest</i> , 2020 , 157, 1266-1277	5.3	18
1119	Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage. <i>Stroke</i> , 2020 , 51, 416-423	6.7	20
1118	Which patients with atrial fibrillation undergo an ablation procedure today in Europe? A report from the ESC-EHRA-EORP Atrial Fibrillation Ablation Long-Term and Atrial Fibrillation General Pilot Registries. <i>Europace</i> , 2020 , 22, 250-258	3.9	2
1117	Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIA Registry. <i>Journal of the American Heart Association</i> , 2020 , 9, e013789	6	11
1116	Temporal trends of catheter ablation for patients with atrial fibrillation: A Korean nationwide population-based study. <i>Journal of Cardiovascular Electrophysiology</i> , 2020 , 31, 2616-2625	2.7	2
1115	Cerebrovascular Dysfunction in Atrial Fibrillation. <i>Frontiers in Physiology</i> , 2020 , 11, 1066	4.6	6
1114	Lipid levels, atrial fibrillation and the impact of age: Results from the LIPIDOGRAM2015 study. <i>Atherosclerosis</i> , 2020 , 312, 16-22	3.1	8
1113	Mobile health technology-supported atrial fibrillation screening and integrated care: A report from the mAFA-II trial Long-term Extension Cohort. <i>European Journal of Internal Medicine</i> , 2020 , 82, 105-111	3.9	39
1112	Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study. <i>American Heart Journal</i> , 2020 , 229, 81-91	4.9	5
1111	Why Is Atrial Fibrillation So Frequent in Hypertensive Patients?. <i>American Journal of Hypertension</i> , 2020 , 33, 1067-1070	2.3	2
1110	Cardiac Electronic Devices: Future Directions and Challenges. <i>Medical Devices: Evidence and Research</i> , 2020 , 13, 325-338	1.5	7
1109	Impacts of Different Renal Function Estimation Formulas on Dosing of DOACs and Clinical Outcomes. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1808-1810	15.1	8

1108	Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study. <i>European Heart Journal</i> , 2020 , 41, 4483-4493	9.5	27
1107	Stroke-Related Visual Impairment; is There an Association with Atrial Fibrillation?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020 , 29, 105186	2.8	
1106	Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials. <i>European Heart Journal Supplements</i> , 2020 , 22, 11-112	1.5	2
1105	A Novel Model for Prediction of Thromboembolic and Cardiovascular Events in Patients Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020 , 131, 40-48	3	2
1104	Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation. <i>Heart Rhythm</i> , 2020 , 17, 2102-2110	6.7	30
1103	Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1867-1881	4	2
1102	Atrial fibrillation and the prothrombotic state: revisiting Virchow's triad in 2020. <i>Heart</i> , 2020 , 106, 1463-1468	3.468	21
1101	Atrial Fibrillation Increases the Risk of Early-Onset Dementia in the General Population: Data from a Population-Based Cohort. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	9
1100	Detection of Atrial Fibrillation on Stroke Units: Look Harder, Look Longer, Look in More Sophisticated Ways. <i>Cerebrovascular Diseases</i> , 2020 , 49, 656-658	3.2	1
1099	Letter by Ding et al Regarding Article, "Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation". <i>Stroke</i> , 2020 , 51, e361-e362	6.7	
1098	Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study. <i>Annals of Internal Medicine</i> , 2020 , 173, 1-9	8	25
1097	Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	3
1096	Vernakalant hydrochloride for the treatment of atrial fibrillation: evaluation of its place in clinical practice. <i>Future Cardiology</i> , 2020 , 16, 585-595	1.3	1
1095	Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 587-600	2.5	3
1094	Utilizing biomarkers associated with cardiovascular events in atrial fibrillation: informing a precision medicine response. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020 , 5, 331-345	1.6	
1093	Family History of Atrial Fibrillation and Risk of Cardiovascular Events: A Multicenter Prospective Cohort Study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e008477	6.4	0
1092	Heart-type fatty acid-binding protein: an overlooked cardiac biomarker. <i>Annals of Medicine</i> , 2020 , 52, 444-461	1.5	6
1091	The CHADS-VASc score and Geriatric Multidimensional Assessment tools in elderly patients with persistent atrial fibrillation undergoing electrical cardioversion. A link with arrhythmia relapse?. <i>European Journal of Internal Medicine</i> , 2020 , 82, 56-61	3.9	3

1090	Hypertension management in cardio-oncology. <i>Journal of Human Hypertension</i> , 2020 , 34, 673-681	2.6	9
1089	A nurse-led atrial fibrillation clinic: Impact on anticoagulation therapy and clinical outcomes. <i>International Journal of Clinical Practice</i> , 2020 , 74, e13634	2.9	5
1088	Anticoagulant Therapy in Initially Low-Risk Patients With Nonvalvular Atrial Fibrillation Who Develop Risk Factors. <i>Journal of the American Heart Association</i> , 2020 , 9, e016271	6	4
1087	Cardiac arrhythmias in patients with COVID-19. <i>Journal of Arrhythmia</i> , 2020 , 36, 827-836	1.5	44
1086	Cardiovascular Events and Mortality in Patients With Atrial Fibrillation and Anemia (from the Fushimi AF Registry). <i>American Journal of Cardiology</i> , 2020 , 134, 74-82	3	7
1085	Role for machine learning in sex-specific prediction of successful electrical cardioversion in atrial fibrillation?. <i>Open Heart</i> , 2020 , 7,	3	6
1084	Sensitivity and specificity of blood-fluid levels for oral anticoagulant-associated intracerebral haemorrhage. <i>Scientific Reports</i> , 2020 , 10, 15529	4.9	1
1083	Treatment implications of renal disease in patients with atrial fibrillation: The BALKAN-AF survey. <i>Journal of Arrhythmia</i> , 2020 , 36, 863-873	1.5	0
1082	The counterintuitive role of exercise in the prevention and cause of atrial fibrillation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020 , 319, H1051-H1058	5.2	4
1081	What Is the Ideal Blood Pressure Threshold for the Prevention of Atrial Fibrillation in Elderly General Population?. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
1080	Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2020 , 383, 1735-1745	59.2	73
1079	Association of enlarged perivascular spaces and anticoagulant-related intracranial hemorrhage. <i>Neurology</i> , 2020 , 95, e2192-e2199	6.5	6
1078	Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The 1MPRESS-AF Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e016239	6	7
1077	Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. <i>PLoS Medicine</i> , 2020 , 17, e1003321	11.6	179
1076	Association between clustering of unhealthy lifestyle factors and risk of new-onset atrial fibrillation: a nationwide population-based study. <i>Scientific Reports</i> , 2020 , 10, 19224	4.9	8
1075	Short-Term Apixaban for Documented Left Atrial Appendage Thrombus in High-Risk Atrial Fibrillation Patients Undergoing Left Atrial Appendage Occlusion. <i>TH Open</i> , 2020 , 4, e351-e353	2.7	0
1074	What do we do about atrial high rate episodes?. <i>European Heart Journal Supplements</i> , 2020 , 22, O42-O52	1.5	12
1073	Association between clinical risk scores and mortality in atrial fibrillation: Systematic review and network meta-regression of 669,000 patients. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 633-644	3.9	11

1072	Bodyweight fluctuation is associated with increased risk of incident atrial fibrillation. <i>Heart Rhythm</i> , 2020 , 17, 365-371	6.7	17
1071	Breaking the rules for studies using real-world observational data: the case of direct-acting anticoagulants and antiepileptic drugs. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 155-156	6.4	3
1070	The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients. <i>Europace</i> , 2020 , 22, 547-557	3.9	23
1069	Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. <i>Europace</i> , 2020 , 22, 33-46	3.9	29
1068	CaseReport: Aldosterone-secreting adrenal carcinoma complicating longstanding hypertension. <i>Journal of Human Hypertension</i> , 2020 , 34, 411-412	2.6	
1067	The safety of discontinuation of oral anticoagulation therapy after apparently successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry study. <i>Europace</i> , 2020 , 22, 90-99	3.9	16
1066	Albuminuria and Risk of Cardiovascular Events and Mortality in a General Population of Patients with Type 2 Diabetes Without Cardiovascular Disease: A Danish Cohort Study. <i>American Journal of Medicine</i> , 2020 , 133, e269-e279	2.4	4
1065	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2950-2973	15.1	1682
1064	Defibrillators for prevention from sudden cardiac death: is it that easy?-Authors' reply. <i>Europace</i> , 2020 , 22, 1298-1299	3.9	
1063	Baseline factors associated with early and late death in intracerebral haemorrhage survivors. <i>European Journal of Neurology</i> , 2020 , 27, 1257-1263	6	3
1062	Device-Pocket Hematoma After Cardiac Implantable Electronic Devices. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e008372	6.4	4
1061	Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 2497-2508	27.4	35
1060	Heart rate variability in atrial fibrillation: The balance between sympathetic and parasympathetic nervous system. <i>European Journal of Clinical Investigation</i> , 2019 , 49, e13174	4.6	30
1059	Association between epicardial adipose tissue and embolic stroke after catheter ablation of atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2019 , 30, 2209-2216	2.7	2
1058	Atrial Fibrillation in Older People: Concepts and Controversies. <i>Frontiers in Medicine</i> , 2019 , 6, 175	4.9	30
1057	The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1901-1919	7	36
1056	Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation. <i>Europace</i> , 2019 , 21, 1297-1306	3.9	9
1055	Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2365-2375	15.1	142

1054	Oral anticoagulation versus antiplatelet or placebo for stroke prevention in patients with heart failure and sinus rhythm: Systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Stroke</i> , 2019 , 14, 856-861	6.3	8
1053	Usefulness of Red Cells Distribution Width to Predict Worse Outcomes in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019 , 124, 1561-1567	3	9
1052	Venous thromboembolism prophylaxis strategies for patients undergoing elective total knee replacement. <i>Lancet Haematology</i> , 2019 , 6, e496-e497	14.6	
1051	Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-level meta-analysis of 141,220 screened individuals. <i>PLoS Medicine</i> , 2019 , 16, e1002903	11.6	56
1050	A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 1119-1125	4.1	2
1049	Body Mass Index Variability and Long-term Risk of New-Onset Atrial Fibrillation in the General Population: A Korean Nationwide Cohort Study. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 225-235	6.4	20
1048	Sex-related risks of recurrence of atrial fibrillation after ablation: Insights from the Guangzhou Atrial Fibrillation Ablation Registry. <i>Archives of Cardiovascular Diseases</i> , 2019 , 112, 171-179	2.7	2
1047	Importance of Risk Reassessment in Patients With Atrial Fibrillation in Guidelines: Assessing Risk as a Dynamic Process. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 611-618	3.8	20
1046	Atrial Fibrillation and Cognitive Function: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 612-619	15.1	67
1045	Safety of direct oral anticoagulants in real-world clinical practice: translating the trials to everyday clinical management. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 187-209	4.1	15
1044	Hypertrophic Cardiomyopathy in Patients with Atrial Fibrillation: Prevalence and Associated Stroke Risks in a Nationwide Cohort Study. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 285-293	7	26
1043	Renal function and outcomes after catheter ablation of patients with atrial fibrillation: The Guangzhou atrial fibrillation ablation registry. <i>Archives of Cardiovascular Diseases</i> , 2019 , 112, 420-429	2.7	10
1042	Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2019 , 50, 2245-2249	6.7	40
1041	Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort. <i>European Heart Journal</i> , 2019 , 40, 2313-2323	9.5	89
1040	Meta-Analysis of Oral Anticoagulant Monotherapy as an Antithrombotic Strategy in Patients With Stable Coronary Artery Disease and Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019 , 124, 879-885	3	16
1039	Efficacy and Safety of Direct Oral Anticoagulants for Risk of Cancer-Associated Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019 , 25, 1076029619853629	3.3	1
1038	Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity-Weighted Cohort Study. <i>Journal of the American Heart Association</i> , 2019 , 8, e011358	6	19
1037	Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. <i>Chest</i> , 2019 , 156, 529-543	5.3	62

1036	Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. <i>Journal of the American Geriatrics Society</i> , 2019 , 67, 1662-1671	5.6	25
1035	Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. <i>Lancet Neurology</i> , 2019 , 18, 653-665	24.1	78
1034	Time-dependent prediction of arrhythmia recurrences during long-term follow-up in patients undergoing catheter ablation of atrial fibrillation: The Leipzig Heart Center AF Ablation Registry. <i>Scientific Reports</i> , 2019 , 9, 7112	4.9	5
1033	Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. <i>Stroke</i> , 2019 , 50, 1372-1379	6.7	29
1032	Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function. <i>Stroke</i> , 2019 , 50, 1480-1489	6.7	8
1031	Microparticles and cardiovascular diseases. <i>Annals of Medicine</i> , 2019 , 51, 193-223	1.5	19
1030	Galectin-3 and Epcam protein concentrations are higher in clinically unaffected patients with Fabry disease. <i>Scientific Reports</i> , 2019 , 9, 6235	4.9	
1029	Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAF-App) II randomised trial. <i>International Journal of Clinical Practice</i> , 2019 , 73, e13352	2.9	36
1028	Glycemic Status and Thromboembolic Risk in Patients With Atrial Fibrillation and Type 2 Diabetes Mellitus: A Danish Cohort Study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019 , 12, e007030	6.4	30
1027	Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation. <i>Scientific Reports</i> , 2019 , 9, 6690	4.9	10
1026	Atrial high-rate episodes and thromboembolism in patients without atrial fibrillation: The West Birmingham Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , 2019 , 292, 126-130	3.2	12
1025	Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association. <i>European Journal of Heart Failure</i> , 2019 , 21, 690-693	12.3	2
1024	Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially 'Low-Risk' Patients. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1162-1170	7	43
1023	The Liverpool Centre for Cardiovascular Science. <i>European Heart Journal</i> , 2019 , 40, 957-958	9.5	
1022	Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. <i>Europace</i> , 2019 , 21, 1013-1022	3.9	28
1021	Stroke and Thromboembolism in Patients With Atrial Fibrillation and Mitral Regurgitation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019 , 12, e006990	6.4	9
1020	Predicting stroke in patients without atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2019 , 49, e13103	4.6	4
1019	Effect of small-vessel disease on cognitive trajectory after atrial fibrillation-related ischaemic stroke or TIA. <i>Journal of Neurology</i> , 2019 , 266, 1250-1259	5.5	11

1018	Optimal Rivaroxaban Dose in Asian Patients With Atrial Fibrillation and Normal or Mildly Impaired Renal Function. <i>Stroke</i> , 2019 , 50, 1140-1148	6.7	24
1017	Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019 , 19, 243-244	2.2	2
1016	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage. <i>Stroke</i> , 2019 , 50, 939-946	6.7	18
1015	Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2019 , 21, 1116-1125	3.9	8
1014	To the Editor- Patients with atrial fibrillation with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?. <i>Heart Rhythm</i> , 2019 , 16, e56	6.7	1
1013	Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention During 2-Year Follow-Up, from a Nationwide Population Study. <i>American Journal of Cardiology</i> , 2019 , 123, 1921-1926	3	4
1012	Safety of drug-eluting stents compared to bare metal stents in patients with an indication for long-term oral anticoagulation: A propensity score matched analysis. <i>Thrombosis Research</i> , 2019 , 177, 180-186	8.2	4
1011	Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study. <i>European Heart Journal</i> , 2019 , 40, 3782-3790	9.5	15
1010	Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 964-972	3.9	7
1009	Stroke: Insights into Thromboembolism Treatment and Prevention through the Decades. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 685-687	7	1
1008	Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 381-398	5.5	21
1007	Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. <i>European Heart Journal</i> , 2019 , 40, 1553-1562	9.5	49
1006	Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 619-633	3.8	35
1005	Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and 'Low' Body Weight. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 919-931	15.1	46
1004	Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. <i>European Journal of Epidemiology</i> , 2019 , 34, 173-190	12.1	35
1003	Stroke risk in female patients with atrial fibrillation: Relationship to current guideline recommendations. <i>Trends in Cardiovascular Medicine</i> , 2019 , 29, 150-152	6.9	1
1002	Secondary stroke prevention and guideline adherent antithrombotic treatment in patients with atrial fibrillation: Insights from the Gulf Survey of atrial fibrillation events (Gulf SAFE). <i>International Journal of Cardiology</i> , 2019 , 274, 126-131	3.2	7
1001	Sex differences in risk of incident venous thromboembolism in heart failure patients. <i>Clinical Research in Cardiology</i> , 2019 , 108, 101-109	6.1	10

1000	ESC Council on hypertension position document on the management of hypertensive emergencies. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 37-46	6.4	68
999	Causes of death in Japanese patients with atrial fibrillation: The Fushimi Atrial Fibrillation Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019 , 5, 35-42	4.6	30
998	2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: an evaluating valvular heart disease in a nationwide cohort study. <i>Europace</i> , 2019 , 21, 33-40	3.9	155
997	Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019 , 5, 127-135	4.6	2
996	Integrated care for the management of atrial fibrillation: what are the key components and important outcomes?. <i>Europace</i> , 2019 , 21, 1759-1761	3.9	2
995	Age-Dependent Prognostic Impact of Paroxysmal Versus Sustained Atrial Fibrillation on the Incidence of Cardiac Death and Heart Failure Hospitalization (the Fushimi AF Registry). <i>American Journal of Cardiology</i> , 2019 , 124, 1420-1429	3	6
994	Considerations when restarting anticoagulants in patients with atrial fibrillation after bleeding. <i>Expert Review of Hematology</i> , 2019 , 12, 845-855	2.8	4
993	Low-Dose Rivaroxaban and Risks of Adverse Events in Patients With Atrial Fibrillation. <i>Stroke</i> , 2019 , 50, 2574-2577	6.7	25
992	Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA). <i>Europace</i> , 2019 , 21, 1603-1604	3.9	33
991	CHEST Score and Prediction of Incident Atrial Fibrillation in Poststroke Patients: A French Nationwide Study. <i>Journal of the American Heart Association</i> , 2019 , 8, e012546	6	42
990	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 83-99	15.1	84
989	Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver Disease. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 3295-3308	15.1	61
988	Improved Population-Based Clinical Outcomes of Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1695-1703	7	85
987	Prevalence and Associated Stroke Risk of Human Immunodeficiency Virus-Infected Patients With Atrial Fibrillation - A Nationwide Cohort Study. <i>Circulation Journal</i> , 2019 , 83, 2547-2554	2.9	0
986	Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	6
985	Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis. <i>Europace</i> , 2019 , 21, 1633-1638	3.9	9
984	Prevalence of modifiable risk factors and relation to stroke and death in patients with atrial fibrillation: A report from the China atrial fibrillation registry study. <i>Journal of Cardiovascular Electrophysiology</i> , 2019 , 30, 2759-2766	2.7	7
983			

982	Prevalence of Hypertension in the Middle Belt of Ghana: A Community-Based Screening Study. <i>International Journal of Hypertension</i> , 2019 , 2019, 1089578	2.4	12
981	Identification of Markers Associated With Development of Stroke in "Clinically Low-Risk" Atrial Fibrillation Patients. <i>Journal of the American Heart Association</i> , 2019 , 8, e012697	6	12
980	Guideline-Adherent Treatment for Stroke and Death in Atrial Fibrillation Patients From UK and Japanese AF Registries. <i>Circulation Journal</i> , 2019 , 83, 2434-2442	2.9	4
979	Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management. <i>Journal of Human Hypertension</i> , 2019 , 33, 824-836	2.6	31
978	Long-Term Persistence with Newly-Initiated Warfarin or Non-VKA Oral Anticoagulant (NOAC) in Patients with Non-Valvular Atrial Fibrillation: Insights from the Prospective China-AF Registry. <i>Medical Science Monitor</i> , 2019 , 25, 2649-2657	3.2	13
977	Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry. <i>Medical Science Monitor</i> , 2019 , 25, 4691-4698	3.2	8
976	Sex Differences in Presentation, Quality of Life, and Treatment in Chinese Atrial Fibrillation Patients: Insights from the China Atrial Fibrillation Registry Study. <i>Medical Science Monitor</i> , 2019 , 25, 8011-8018	3.2	7
975	Revisiting the risks of incident atrial fibrillation: a narrative review. Part 2. <i>Kardiologia Polska</i> , 2019 , 77, 515-524	0.9	2
974	Pulse pressure and prognosis in patients with heart failure with reduced ejection fraction. <i>European Journal of Clinical Investigation</i> , 2019 , 49, e13092	4.6	1
973	Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. <i>American Heart Journal</i> , 2019 , 212, 13-22	4.9	8
972	Recommendations on stroke prevention for patients having a CHADS-VASc score of 1 (males) or 2 (females) in 2019 atrial fibrillation guidelines. <i>Trends in Cardiovascular Medicine</i> , 2019 , 29, 427-428	6.9	5
971	Atrial high rate episodes in patients with cardiac implantable electronic devices: implications for clinical outcomes. <i>Clinical Research in Cardiology</i> , 2019 , 108, 1034-1041	6.1	13
970	EHRA White Paper: knowledge gaps in arrhythmia management-status 2019. <i>Europace</i> , 2019 , 21, 993-994	3.9	23
969	Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. <i>BMJ Open</i> , 2019 , 9, e033712	3	0
968	Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). <i>Europace</i> , 2019	3.9	30
967	Differences in outcomes between oral anticoagulation "new starters" and "switchers" in patients with nonvalvular atrial fibrillation: A pooled analysis of the AMADEUS and BOREALIS trials. <i>Journal of Arrhythmia</i> , 2019 , 35, 815-820	1.5	
966	Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e008160	6	0
965	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asians With Nonvalvular Atrial Fibrillation: A Network Meta-Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019 , 25, 1076023	3.3	19885188

964	Thromboembolic risks associated with paroxysmal and persistent atrial fibrillation in Asian patients: a report from the Chinese atrial fibrillation registry. <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 283	2.3	7
963	Etiologic workup in cases of cryptogenic stroke: protocol for a systematic review and comparison of international clinical practice guidelines. <i>Systematic Reviews</i> , 2019 , 8, 331	3	2
962	Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 2427-2436	6.4	36
961	Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis. <i>Cardiovascular Drugs and Therapy</i> , 2019 , 33, 701-710	3.9	16
960	Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 2331-2341	5	3
959	Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration. <i>Circulation</i> , 2019 , 140, 1834-1850	16.7	93
958	Should We Judge Stroke Risk by Static or Dynamic Risk Scores? A Focus on the Dynamic Nature of Stroke and Bleeding Risks in Patients With Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology</i> , 2019 , 74, 491-498	3.1	5
957	Risk Stratification for Ischemic Cerebrovascular Events and Mortality among Intracerebral Hemorrhage Patients with and without Atrial Fibrillation: A Nationwide Cohort Study. <i>Cerebrovascular Diseases</i> , 2019 , 48, 236-243	3.2	4
956	Effectiveness and Safety of Direct Oral Anticoagulant for Secondary Prevention in Asians with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	16
955	Novel Echocardiographic Biomarkers in the Management of Atrial Fibrillation. <i>Current Cardiovascular Imaging Reports</i> , 2019 , 12, 1	0.7	3
954	Fluctuating renal function and the risk of incident atrial fibrillation: a nationwide population-based study. <i>Scientific Reports</i> , 2019 , 9, 18055	4.9	3
953	Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program. <i>American Heart Journal</i> , 2019 , 218, 123-127	4.9	8
952	One-year risks of stroke and mortality in patients with atrial fibrillation from different clinical settings: The Gulf SAFE registry and Darlington AF registry. <i>International Journal of Cardiology</i> , 2019 , 274, 158-162	3.2	6
951	Use of Oral Anticoagulation in Patients With Atrial Fibrillation and End-stage Renal Disease: What Is Needed Nowadays? Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019 , 72, 97-98	0.7	
950	Stroke prevention in atrial fibrillation: State of the art. <i>International Journal of Cardiology</i> , 2019 , 287, 201-209	3.2	7
949	Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials. <i>American Journal of Cardiovascular Drugs</i> , 2019 , 19, 37-47	4	5
948	Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 508-515	3.8	14
947	Elevated blood plasma levels of tissue factor-bearing extracellular vesicles in patients with atrial fibrillation. <i>Thrombosis Research</i> , 2019 , 173, 141-150	8.2	11

946	Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF Study Cohort. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1261-1267	6.4	57
945	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 14-38	7	19
944	Thrombosis and Haemostasis 2018 Editor's Choice Papers. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 183-186	2	
943	Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities. <i>European Heart Journal</i> , 2019 , 40, 1504-1514	9.5	51
942	Response by Chao et al to Letter Regarding Article, "Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study". <i>Circulation</i> , 2019 , 139, 146-147	16.7	1
941	Reassessment of Risk for Stroke During Follow-up of Patients With Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2019 , 170, 663-664	8	15
940	Relation of the CHADS-VASc Score to Risk of Thrombotic and Embolic Stroke in Community-Dwelling Individuals Without Atrial Fibrillation (From The Atherosclerosis Risk in Communities [ARIC] Study). <i>American Journal of Cardiology</i> , 2019 , 123, 402-408	3	11
939	Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF). <i>American Journal of Cardiology</i> , 2019 , 123, 592-597	3	6
938	Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 320-325	5.5	31
937	Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study. <i>PLoS ONE</i> , 2019 , 14, e0209593	3.7	14
936	ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study. <i>American Journal of Medicine</i> , 2019 , 132, 856-861	2.4	39
935	Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population. <i>European Heart Journal</i> , 2019 , 40, 809-819	9.5	51
934	Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Nationwide Cohort Study. <i>Chest</i> , 2019 , 155, 354-363	5.3	39
933	Anticoagulación oral en pacientes con fibrilación auricular e insuficiencia renal terminal: ¿cuál es lo más apropiado? Respuesta. <i>Revista Española De Cardiología</i> , 2019 , 72, 97-98	1.5	
932	Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. <i>European Heart Journal</i> , 2019 , 40, 1268-1276	9.5	67
931	The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. <i>International Journal of Clinical Practice</i> , 2019 , 73, e13285	2.9	7
930	The prothrombotic state in atrial fibrillation: pathophysiological and management implications. <i>Cardiovascular Research</i> , 2019 , 115, 31-45	9.9	43
929	A Simple Clinical Risk Score (CHEST) for Predicting Incident Atrial Fibrillation in Asian Subjects: Derivation in 471,446 Chinese Subjects, With Internal Validation and External Application in 451,199 Korean Subjects. <i>Chest</i> , 2019 , 155, 510-518	5.3	64

928	Time trends in use of the CHADS and CHA ₂ DS VASc scores, and the geographical and specialty uptake of these scores from a popular online clinical decision tool and medical reference. <i>International Journal of Clinical Practice</i> , 2019 , 73, e13280	2.9	4
927	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. <i>Europace</i> , 2019 ,	3.9	59
926	In-hospital direct costs for thromboembolism and bleeding in Chinese patients with atrial fibrillation. <i>Chronic Diseases and Translational Medicine</i> , 2018 , 4, 127-134	3.9	3
925	Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 768-777	7	88
924	Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study. <i>Circulation</i> , 2018 , 138, 37-47	16.7	136
923	Role of Monocytes in Heart Failure and Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	45
922	Epidemiology of atrial fibrillation. <i>International Journal of Clinical Practice</i> , 2018 , 72, e13070	2.9	80
921	Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015. <i>Heart</i> , 2018 , 104, 2010-2017	5.1	69
920	Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program. <i>American Journal of Medicine</i> , 2018 , 131, 945-955.e3	2.4	21
919	Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2018 , 54, 34-39	3.9	14
918	Inflammation and the risk of atrial high-rate episodes (AHREs) in patients with cardiac implantable electronic devices. <i>Clinical Research in Cardiology</i> , 2018 , 107, 772-777	6.1	19
917	Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2018 , 48, e12929	4.6	1
916	Relationship of troponin to incident atrial fibrillation occurrence, recurrence after radiofrequency ablation and prognosis: a systematic review, meta-analysis and meta-regression. <i>Biomarkers</i> , 2018 , 23, 512-517	2.6	9
915	Risk factors for new-onset atrial fibrillation: A focus on Asian populations. <i>International Journal of Cardiology</i> , 2018 , 261, 92-98	3.2	24
914	Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2018 , 39, 1726-1735a	9.5	112
913	Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. <i>Europace</i> , 2018 , 20, 747-757	3.9	81
912	Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHADS ₂ -VA Score Rather Than CHADS ₂ -VASc?. <i>Circulation</i> , 2018 , 137, 832-840	16.7	93
911	Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: Attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study. <i>International Journal of Cardiology</i> , 2018 , 254, 157-161	3.2	43

910	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. <i>Europace</i> , 2018 , 20, e1-e160	3.9	461
909	Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality. <i>International Journal of Clinical Practice</i> , 2018 , 72, e13069	2.9	1
908	Relation of quality of anticoagulation control with different management systems among patients with atrial fibrillation: Data from FANTASIA Registry. <i>European Journal of Clinical Investigation</i> , 2018 , 48, e12910	4.6	4
907	Risk of stroke and bleeding in patients with heart failure and chronic kidney disease: a nationwide cohort study. <i>ESC Heart Failure</i> , 2018 , 5, 319-326	3.7	5
906	Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIA registry. <i>Europace</i> , 2018 , 20, 1435-1441	3.9	33
905	Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIA Registry. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 279-287	7	8
904	Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP).	3.9	81
903	Impact of Mon2 monocyte-platelet aggregates on human coronary artery disease. <i>European Journal of Clinical Investigation</i> , 2018 , 48, e12911	4.6	4
902	Arterial hypertension in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme pilot survey on atrial fibrillation. <i>International Journal of Cardiology</i> , 2018 , 254, 136-141	3.2	6
901	Modelling projections for the risks related with atrial fibrillation in East Asia: a focus on ischaemic stroke and death. <i>Europace</i> , 2018 , 20, 1584-1590	3.9	7
900	Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2018 , 29, 566-572	2.7	16
899	The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants. <i>American Journal of Medicine</i> , 2018 , 131, 574.e13-574.e27	2.4	29
898	Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. <i>Clinical Therapeutics</i> , 2018 , 40, 114-122	3.5	17
897	Relationship of peripheral and coronary artery disease to cardiovascular events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2018 , 255, 69-73	3.2	17
896	Quantifying Time in Atrial Fibrillation and the Need for Anticoagulation. <i>Progress in Cardiovascular Diseases</i> , 2018 , 60, 537-541	8.5	7
895	Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 122-132	15.1	114
894	Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation. <i>American Heart Journal</i> , 2018 , 198, 39-45	4.9	19
893	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018 , 20, 395-407	3.9	66

892	Editors' Choice in the 60th Anniversary Year of Thrombosis and Haemostasis: Past, Present and Future. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 225-227	7	1
891	A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 1065-1073	6.4	18
890	10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population. <i>American Heart Journal</i> , 2018 , 202, 20-26	4.9	71
889	Dynamic Changes of CHA2DS2-VASc Score and the Risk of Ischaemic Stroke in Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1296-1304	7	76
888	Predictors of diastolic dysfunction in ethnic groups: observations from the Hypertensive Cohort of The Ethnic-Echocardiographic Heart of England Screening Study (E-ECHOES). <i>Journal of Human Hypertension</i> , 2018 , 32, 477-486	2.6	3
887	Variations of Prevalence and Incidence of Atrial Fibrillation and Oral Anticoagulation Rate According to Different Analysis Approaches. <i>Scientific Reports</i> , 2018 , 8, 6856	4.9	13
886	Prognostic and therapeutic implications of vascular disease in patients with atrial fibrillation. <i>Pharmacological Research</i> , 2018 , 132, 149-159	10.2	7
885	Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1868-1882	3.8	21
884	Atrial fibrillation in the Middle East: unmapped, underdiagnosed, undertreated. <i>Expert Review of Cardiovascular Therapy</i> , 2018 , 16, 341-348	2.5	8
883	Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice. <i>Annals of Medicine</i> , 2018 , 50, 288-302	1.5	10
882	Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. <i>Nature Reviews Nephrology</i> , 2018 , 14, 337-351	14.9	50
881	Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naïve patients with atrial fibrillation. <i>American Heart Journal</i> , 2018 , 200, 32-36	4.9	11
880	Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2018 , 261, 84-91	3.2	15
879	Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program. <i>Clinical Cardiology</i> , 2018 , 41, 744-751	3.3	14
878	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. <i>Heart Rhythm</i> , 2018 , 15, e37-e60	6.7	16
877	Predicting recurrent atrial fibrillation after catheter ablation. <i>Europace</i> , 2018 , 20, f460-f461	3.9	5
876	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , 2018 , 20, 1231-1242	3.9	148
875	Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 626-634	5	19

874	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018 , 39, 1330-1393	9.5	1094
873	Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification. <i>International Journal of Cardiology</i> , 2018 , 260, 93-98	3.2	10
872	Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation. <i>Europace</i> , 2018 , 20, 243-252	3.9	28
871	Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapy (RE-LY) study. <i>Europace</i> , 2018 , 20, 253-262	3.9	10
870	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2018 , 39, 119-177	9.5	4237
869	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2018 , 39, 312-318	9.5	1475
868	Lifetime Risks, Projected Numbers, and Adverse Outcomes in Asian Patients With Atrial Fibrillation: A Report From the Taiwan Nationwide AF Cohort Study. <i>Chest</i> , 2018 , 153, 453-466	5.3	65
867	Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis. <i>Age and Ageing</i> , 2018 , 47, 9-17	3	45
866	Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF). <i>Heart and Vessels</i> , 2018 , 33, 403-412	2.1	18
865	Comparing Bleeding Risk Assessment Focused on Modifiable Risk Factors Only Versus Validated Bleeding Risk Scores in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2018 , 131, 185-192	2.4	40
864	Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. <i>Journal of Internal Medicine</i> , 2018 , 283, 45-55	10.8	61
863	Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry. <i>American Heart Journal</i> , 2018 , 198, 55-63	4.9	30
862	Enhancing the 'real world' prediction of cardiovascular events and major bleeding with the CHADS-VASc and HAS-BLED scores using multiple biomarkers. <i>Annals of Medicine</i> , 2018 , 50, 26-34	1.5	14
861	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE). <i>European Heart Journal</i> , 2018 , 39, 1442-1445	9.5	24
860	Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA). <i>Annals of Medicine</i> , 2018 , 50, 511-518	1.5	7
859	Heart Failure and Stroke. <i>Current Heart Failure Reports</i> , 2018 , 15, 287-296	2.8	7
858	Stroke Prevention in Atrial Fibrillation: Focus on Asian Patients. <i>Korean Circulation Journal</i> , 2018 , 48, 665-684	2.2	31
857	Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban. <i>PLoS ONE</i> , 2018 , 13, e0195950	3.7	33

856	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. <i>Circulation Journal</i> , 2018 , 82, 1286-1292	2.9	3
855	Reply to 'Comment on 'Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized clinical trials' by Tse et al.'. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2165-2166	3.8	1
854	Sex differences in stroke and major adverse clinical events in patients with atrial fibrillation: A systematic review and meta-analysis of 993,600 patients. <i>International Journal of Cardiology</i> , 2018 , 269, 182-191	3.2	31
853	Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 271-282	15.1	37
852	Stroke Prophylaxis After a New Emergency Department Diagnosis of Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 471-472	15.1	3
851	Age Threshold for Ischemic Stroke Risk in Atrial Fibrillation. <i>Stroke</i> , 2018 , 49, 1872-1879	6.7	19
850	Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry. <i>International Journal of Cardiology</i> , 2018 , 271, 68-74	3.2	23
849	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?. <i>Journal of Arrhythmia</i> , 2018 , 34, 99-123	1.5	7
848	Risk of incident atrial fibrillation in patients presenting with retinal artery or vein occlusion: a nationwide cohort study. <i>BMC Cardiovascular Disorders</i> , 2018 , 18, 91	2.3	12
847	Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study. <i>BMJ Open</i> , 2018 , 8, e020191 ³		9
846	Edoxaban in Asian Patients With Atrial Fibrillation: Effectiveness and Safety. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 838-853	15.1	67
845	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018 , 39, 3021-3104	9.5	3698
844	Using the MB-LATER score for predicting arrhythmia outcome after catheter ablation for atrial fibrillation: The Guangzhou atrial fibrillation project. <i>International Journal of Clinical Practice</i> , 2018 , 72, e13247	2.9	8
843	Acute hydrocortisone administration reduces cardiovagal baroreflex sensitivity and heart rate variability in young men. <i>Journal of Physiology</i> , 2018 , 596, 4847-4861	3.9	8
842	Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. <i>American Journal of Medicine</i> , 2018 , 131, 1359-1366.e6	2.4	71
841	Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2018 , 154, 1121-1201	5.3	502
840	Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018 , 122, 785-792	3	8
839	Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study. <i>PLoS ONE</i> , 2018 , 13, e0189936	3.7	23

838	Translating guidelines into practice for the management of atrial fibrillation: results of an European Heart Rhythm Association Survey. <i>Europace</i> , 2018 , 20, 1382-1387	3.9	11
837	Incidence and Risk Factors of Stroke or Systemic Embolism in Patients With Atrial Fibrillation and Heart Failure - The Fushimi AF Registry. <i>Circulation Journal</i> , 2018 , 82, 1327-1335	2.9	20
836	Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. <i>PLoS ONE</i> , 2018 , 13, e0191722	3.7	27
835	NONinvasive Monitoring for Early Detection of Atrial Fibrillation: rationale and design of the NOMED-AF study. <i>Kardiologia Polska</i> , 2018 , 76, 1482-1485	0.9	6
834	Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials. <i>Circulation</i> , 2018 , 137, 1117-1129	16.7	33
833	Use of the SAME-TTR score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: A review. <i>Heart Rhythm</i> , 2018 , 15, 615-623	6.7	17
832	Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the Edoxaban versus warfarin in subjects Undergoing cardioversion of Atrial Fibrillation [ENSURE-AF] Study). <i>American Journal of Cardiology</i> , 2018 , 121, 193-198	3	5
831	New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 71-86	5.9	7
830	Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials. <i>International Journal of Cardiology</i> , 2018 , 252, 96-100	3.2	6
829	Prediction of Incident Atrial Fibrillation According to Gender in Patients With Ischemic Stroke From a Nationwide Cohort. <i>American Journal of Cardiology</i> , 2018 , 121, 437-444	3	12
828	Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Stroke</i> , 2018 , 49, 98-106	6.7	67
827	P3845 Use of oral anticoagulation and association to outcomes in atrial fibrillation patients who develop chronic kidney disease: a nationwide cohort study. <i>European Heart Journal</i> , 2018 , 39,	9.5	1
826	2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2018 , 36, 2284-2309	1.9	372
825	Stroke Risk Stratification for Atrial Fibrillation Patients With Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2409-2411	15.1	12
824	Letter by Shahid and Lip Regarding Article, "Stroke Risk Factors Unique to Women". <i>Stroke</i> , 2018 , 49, e290	6.7	
823	Should the Presence or Extent of Coronary Artery Disease be Quantified in the CHA2DS2-VASc Score in Atrial Fibrillation? A Report from the Western Denmark Heart Registry. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 2162-2170	7	22
822	2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>Blood Pressure</i> , 2018 , 27, 314-340	1.7	132
821	Renal Function and Risk Stratification of Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2018 , 49, 2904-2909	6.7	2

820	Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. <i>Stroke</i> , 2018 , 49, 2933-2944	6.7	157
819	2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2018 , 36, 219-262	1.9	1262
818	Progression From Paroxysmal to Sustained Atrial Fibrillation Is Associated With Increased Adverse Events. <i>Stroke</i> , 2018 , 49, 2301-2308	6.7	39
817	Associations between socioeconomic status, atrial fibrillation, and outcomes: a systematic review. <i>Expert Review of Cardiovascular Therapy</i> , 2018 , 16, 857-873	2.5	12
816	Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation. <i>Stroke</i> , 2018 , 49, 2421-2429	6.7	28
815	Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation - The Fushimi AF Registry. <i>Circulation Journal</i> , 2018 , 82, 2983-2991	2.9	12
814	Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. <i>PLoS ONE</i> , 2018 , 13, e0205989	3.7	34
813	Evolving Changes of the Use of Oral Anticoagulants and Outcomes in Patients With Newly Diagnosed Atrial Fibrillation in Taiwan. <i>Circulation</i> , 2018 , 138, 1485-1487	16.7	44
812	Multiple biomarkers and arrhythmia outcome following catheter ablation of atrial fibrillation: The Guangzhou Atrial Fibrillation Project. <i>Journal of Arrhythmia</i> , 2018 , 34, 617-625	1.5	4
811	Usefulness of the CHADS-VASc Score to Predict the Risk of Sudden Cardiac Death and Ventricular Arrhythmias in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018 , 122, 2049-2054	3	7
810	Disease progression after ablation for atrial flutter compared with atrial fibrillation: A nationwide cohort study. <i>International Journal of Clinical Practice</i> , 2018 , 72, e13258	2.9	7
809	Ideal Blood Pressure in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1233-1245	15.1	63
808	A U-shaped relationship of body mass index on atrial fibrillation recurrence post ablation: A report from the Guangzhou atrial fibrillation ablation registry. <i>EBioMedicine</i> , 2018 , 35, 40-45	8.8	12
807	Patients' Perceptions of Atrial Fibrillation, Stroke Risk, and Oral Anticoagulation Treatment: An International Survey. <i>TH Open</i> , 2018 , 2, e233-e241	2.7	9
806	The Importance and Future of Population Screening for Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1407-1411	3.8	2
805	Anticoagulation Resumption After Intracerebral Hemorrhage. <i>Current Atherosclerosis Reports</i> , 2018 , 20, 32	6	27
804	Rivaroxaban for stroke prevention in people with atrial fibrillation and diabetes mellitus. <i>Diabetic Medicine</i> , 2018 , 35, 1134-1135	3.5	1
803	Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. <i>European Journal of Internal Medicine</i> , 2018 , 55, 28-34	3.9	37

802	Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. <i>Lancet Neurology, The</i> , 2018 , 17, 539-547	24.1	134
801	Nonvitamin K Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Renal Dysfunction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018 , 71, 847-855	0.7	3
800	Impact of aerobic fitness on cerebral blood flow and cerebral vascular responsiveness to CO in young and older men. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2017 , 27, 634-642	4.6	15
799	EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. <i>Heart Rhythm</i> , 2017 , 14, e3-e40	6.7	138
798	Atrial Fibrillation Diagnosis Timing, Ambulatory ECG Monitoring Utilization, and Risk of Recurrent Stroke. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017 , 10,	5.8	26
797	Prediction of very late arrhythmia recurrence after radiofrequency catheter ablation of atrial fibrillation: The MB-LATER clinical score. <i>Scientific Reports</i> , 2017 , 7, 40828	4.9	46
796	Novel Risk Markers and Risk Assessments for Cardiovascular Disease. <i>Circulation Research</i> , 2017 , 120, 133-149	15.7	80
795	Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?. <i>Scientific Reports</i> , 2017 , 7, 41565	4.9	25
794	Risk Stratification Models in Atrial Fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , 2017 , 43, 505-513	5.3	8
793	Ischemic stroke risk in East Asian patients with CHADS-VASc score of 1: systematic review and meta-analysis. <i>Expert Review of Cardiovascular Therapy</i> , 2017 , 15, 145-150	2.5	4
792	Postapproval Observational Studies of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 1115-1116	27.4	28
791	The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 777-785	15.1	193
790	Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis. <i>Stroke</i> , 2017 , 48, 970-976	6.7	74
789	Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation. <i>JAMA Internal Medicine</i> , 2017 , 177, 563-570	11.5	58
788	Is There an Obesity Paradox for Outcomes in Atrial Fibrillation? A Systematic Review and Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulant Trials. <i>Stroke</i> , 2017 , 48, 857-866	6.7	79
787	Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry. <i>Clinical Research in Cardiology</i> , 2017 , 106, 420-427	6.1	4
786	Reply: Apixaban Dosing in Chronic Kidney Disease: Differences Between U.S. and E.U. Labeling. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1212	15.1	1
785	Decision-making interventions to stop the global atrial fibrillation-related stroke tsunami. <i>International Journal of Stroke</i> , 2017 , 12, 222-228	6.3	12

784	Pulmonary Embolism and Atrial Fibrillation: Two Sides of the Same Coin? A Systematic Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2017 , 43, 849-863	5.3	33
783	The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. <i>Clinical Research in Cardiology</i> , 2017 , 106, 565-572	6.1	40
782	Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. <i>Lancet Haematology</i> , 2017 , 4, e237-e244	14.6	29
781	The Global Burden of Atrial Fibrillation and Stroke: A Systematic Review of the Clinical Epidemiology of Atrial Fibrillation in Asia. <i>Chest</i> , 2017 , 152, 810-820	5.3	71
780	Risk and Prediction of Sudden Cardiac Death and Ventricular Arrhythmias for Patients with Atrial Fibrillation - A Nationwide Cohort Study. <i>Scientific Reports</i> , 2017 , 7, 46445	4.9	23
779	Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. <i>Circulation</i> , 2017 , 135, 1851-1867	16.7	302
778	Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. <i>American Heart Journal</i> , 2017 , 190, 12-18	4.9	143
777	Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	127
776	CHADS-VASc Score (Congestive Heart Failure, Hypertension, Age ≥ 75 [Doubled], Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack [Doubled], Vascular Disease, Age 65-74, Female) for Stroke in Asian Patients With Atrial Fibrillation: A Korean Nationwide Sample Cohort Study. <i>Stroke</i> , 2017 , 48, 1524-1530	6.7	76
775	Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project. <i>Clinical Cardiology</i> , 2017 , 40, 222-229	3.3	37
774	Cerebrovascular disease, associated risk factors and antithrombotic therapy in a population screening cohort: Insights from the Belgian Heart Rhythm Week programme. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 328-334	3.9	9
773	Predicting Unsuccessful Electrical Cardioversion for Acute Atrial Fibrillation (from the AF-CVS Score). <i>American Journal of Cardiology</i> , 2017 , 119, 749-752	3	15
772	Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Cardíaca y Electrofisiología (SOLEACE). <i>Europace</i> , 2017 , 19, 891-911	3.9	58
771	Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: a systematic review. <i>Clinical Research in Cardiology</i> , 2017 , 106, 813-823	6.1	41
770	Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study. <i>JAMA Cardiology</i> , 2017 , 2, 872-881	16.2	34
769	Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry. <i>American Heart Journal</i> , 2017 , 190, 86-93	4.9	14
768	Intra-cardiac and peripheral levels of biochemical markers of fibrosis in patients undergoing catheter ablation for atrial fibrillation. <i>Europace</i> , 2017 , 19, 1944-1950	3.9	15
767	Malignant Hypertension Revisited-Does This Still Exist?. <i>American Journal of Hypertension</i> , 2017 , 30, 543-549	5.4	25

766	The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden. <i>Europace</i> , 2017 , 19, 1767-1775	3.9	4
765	Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries. <i>EBioMedicine</i> , 2017 , 18, 199-203	8.8	11
764	Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 1151-1158	11.4	98
763	Viewpoint: Stroke Prevention in Recent Guidelines for the Management of Patients with Atrial Fibrillation: An Appraisal. <i>American Journal of Medicine</i> , 2017 , 130, 773-779	2.4	4
762	Hypertension and Atrial Fibrillation: An Intimate Association of Epidemiology, Pathophysiology, and Outcomes. <i>American Journal of Hypertension</i> , 2017 , 30, 733-755	2.3	37
761	Geographical differences in thromboembolic and bleeding risks in patients with non-valvular atrial fibrillation: An ancillary analysis from the SPORTIF trials. <i>International Journal of Cardiology</i> , 2017 , 236, 244-248	3.2	1
760	Ethnic differences in the prevalence of peripheral arterial disease: a systematic review and meta-analysis. <i>Expert Review of Cardiovascular Therapy</i> , 2017 , 15, 327-338	2.5	26
759	Patients' experiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: A qualitative study. <i>Thrombosis Research</i> , 2017 , 153, 19-27	8.2	25
758	Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation. <i>Europace</i> , 2017 , 19, 1439-1448	12.8	34
757	Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor. <i>Advances in Therapy</i> , 2017 , 34, 357-377	4.1	10
756	The ABC pathway: an integrated approach to improve AF management. <i>Nature Reviews Cardiology</i> , 2017 , 14, 627-628	14.8	189
755	Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation. <i>Stroke</i> , 2017 , 48, 3040-3048	6.7	94
754	Systolic Blood Pressure Visit-to-Visit Variability and Major Adverse Outcomes in Atrial Fibrillation: The AFFIRM Study (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). <i>Hypertension</i> , 2017 , 70, 949-958	8.5	16
753	Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study. <i>American Heart Journal</i> , 2017 , 194, 99-106	4.9	25
752	Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. <i>Europace</i> , 2017 , 19, 1630-1636	3.9	10
751	Response to: The Cause of the Arteriolar Injury in Malignant Hypertension. <i>American Journal of Hypertension</i> , 2017 , 30, e15	2.3	
750	Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1848-1858	7	44
749	Editors' Choice 2016 papers in Thrombosis and Haemostasis. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 204-206	7	9

748	Improvement and Aggravation of Spontaneous Unruptured Vertebral Artery Dissection. <i>Cerebrovascular Diseases Extra</i> , 2017 , 7, 153-164	2.1	9
747	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017 , 38, 1455-1462	9.5	63
746	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>Europace</i> , 2017 , 19, 190-225	3.9	44
745	Death and thrombo-embolic risk after ablation of atrial flutter compared with atrial fibrillation: a nationwide cohort study. <i>Europace</i> , 2017 , 19, 838-842	3.9	7
744	Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. <i>Europace</i> , 2017 , 19, 535-543	3.9	26
743	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2017 , 38, 852-859	9.5	50
742	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017 , 38, 860-868	9.5	75
741	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017 , 19, 1390-1400	12.3	111
740	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2017 , 377, 1513-1524	59.2	804
739	Persistency of left atrial linear lesions after radiofrequency catheter ablation for atrial fibrillation: Data from an invasive follow-up electrophysiology study. <i>Journal of Cardiovascular Electrophysiology</i> , 2017 , 28, 1403-1414	2.7	8
738	Is atrial fibrillation another manifestation of organ damage in diabetes?. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 761-762	18.1	1
737	Hypertension and Atrial Fibrillation: Balancing Stroke and Bleeding Risks. <i>American Journal of Hypertension</i> , 2017 , 30, 1063-1065	2.3	8
736	Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial. <i>American Journal of Medicine</i> , 2017 , 130, 1388-1396	2.4	110
735	Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1573-1583	15.1	28
734	Direct oral anticoagulant reversal: how, when and issues faced. <i>Expert Review of Hematology</i> , 2017 , 10, 1005-1022	2.8	2
733	Atrial Fibrillation and Hypertension. <i>Hypertension</i> , 2017 , 70, 854-861	8.5	62
732	Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. <i>Scientific Reports</i> , 2017 , 7, 12066	4.9	14
731	CHADS-VASc Score for Identifying Truly Low-Risk Atrial Fibrillation for Stroke: A Korean Nationwide Cohort Study. <i>Stroke</i> , 2017 , 48, 2984-2990	6.7	56

730	Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase. <i>International Journal of Cardiology</i> , 2017 , 248, 166-172	3.2	6
729	All Types of Hemorrhagic Stroke Are Not Created Equally-Reply. <i>JAMA Internal Medicine</i> , 2017 , 177, 1399-1405	1.5	
728	Bleeding Risk Scores in Atrial Fibrillation and Venous Thromboembolism. <i>American Journal of Cardiology</i> , 2017 , 120, 1139-1145	3	32
727	Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists. <i>International Journal of Clinical Practice</i> , 2017 , 71, e12974	2.9	2
726	Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. <i>Neurology</i> , 2017 , 89, 687-696	6.5	53
725	Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHADS-VASc Scores. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	26
724	A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. <i>BMJ Open</i> , 2017 , 7, e015099	3	29
723	Clinical implications, benefits and pitfalls of using and reversing non-vitamin K antagonist oral anticoagulants. <i>Expert Review of Hematology</i> , 2017 , 10, 833-845	2.8	1
722	Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial). <i>American Journal of Cardiology</i> , 2017 , 120, 792-796	3	12
721	Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Stroke</i> , 2017 , 48, 2494-2503	6.7	130
720	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 419-431	3.9	30
719	Peripheral arterial disease amongst British ethnic minorities in a community based population: The Ethnic-Echocardiographic Heart of England Screening Study (E-ECHOES). <i>International Journal of Clinical Practice</i> , 2017 , 71, e12977	2.9	1
718	The relationship of renal function to outcome: A post hoc analysis from the Edoxaban versus warfarin in subjects Undergoing cardioversion of Atrial Fibrillation (ENSURE-AF) study. <i>American Heart Journal</i> , 2017 , 193, 16-22	4.9	5
717	Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation: Insights From the Community-Based Darlington Atrial Fibrillation Registry. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 1203-1213	6.4	28
716	Coronary artery disease and risk of adverse cardiac events and stroke. <i>European Journal of Clinical Investigation</i> , 2017 , 47, 819-828	4.6	13
715	The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey. <i>Advances in Therapy</i> , 2017 , 34, 2043-2057	4.1	13
714	Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban. <i>American Journal of Cardiology</i> , 2017 , 120, 1689-1695	3	20
713	Outcome of octogenarians with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. <i>Clinical Cardiology</i> , 2017 , 40, 1264-1270	3.3	2

712	Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. <i>European Heart Journal</i> , 2017 , 38, 899-906	9.5	127
711	Liver Cirrhosis in Patients With Atrial Fibrillation: Would Oral Anticoagulation Have a Net Clinical Benefit for Stroke Prevention?. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	57
710	Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1101-1114	4	7
709	Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 1051-1062	4.1	13
708	Secondary Versus Primary Stroke Prevention in Atrial Fibrillation: Insights From the Darlington Atrial Fibrillation Registry. <i>Stroke</i> , 2017 , 48, 2198-2205	6.7	17
707	P-Wave Indices and Risk of Ischemic Stroke: A Systematic Review and Meta-Analysis. <i>Stroke</i> , 2017 , 48, 2066-2072	6.7	64
706	External Validation of the Simple NULL-PLEASE Clinical Score in Predicting Outcome of Out-of-Hospital Cardiac Arrest. <i>American Journal of Medicine</i> , 2017 , 130, 1464.e13-1464.e21	2.4	12
705	Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study. <i>International Journal of Cardiology</i> , 2017 , 227, 644-649	3.2	50
704	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 4-40	3.9	43
703	Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. <i>Circulation</i> , 2017 , 135, 323-333	16.7	72
702	Applicability of the modified CHADS-VASc score for stroke risk stratification in Caucasian atrial fibrillation patients. <i>European Journal of Internal Medicine</i> , 2017 , 38, e21-e22	3.9	2
701	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardiac y Electrofisiologia (SOLECE). <i>Europace</i> , 2017 , 19, 145-147	3.9	85
700	Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice. <i>American Journal of Medicine</i> , 2017 , 130, 135-145	2.4	33
699	Prognosis in patients with atrial fibrillation and a presumed "temporary cause" in a community-based cohort study. <i>Clinical Research in Cardiology</i> , 2017 , 106, 202-210	6.1	18
698	Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 37-41	6.4	22
697	Increased sympathetic nerve activity and reduced cardiac baroreflex sensitivity in rheumatoid arthritis. <i>Journal of Physiology</i> , 2017 , 595, 967-981	3.9	43
696	Relationship between renal function and circulating microparticles, soluble P-selectin and E-selectin levels in atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 43, 18-23	5.1	11
695	Current Understanding of Atherogenesis. <i>American Journal of Medicine</i> , 2017 , 130, 268-282	2.4	52

694	Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting. <i>Interventional Cardiology Clinics</i> , 2017 , 6, 91-117	1.4	3
693	Renal dysfunction and diastolic impairment among British ethnic minorities with hypertension: the Ethnic-Echocardiographic Heart of England Screening Study. <i>Journal of Human Hypertension</i> , 2017 , 31, 206-211	2.6	
692	Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1448-1454	7	55
691	Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1230-1239	7	265
690	Atrial high-rate episodes and stroke prevention. <i>Europace</i> , 2017 , 19, 169-179	3.9	58
689	Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de	3.9	137
688	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLAECE). <i>Europace</i> , 2017 , 19, 1588-1593	3.9	135
687	Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia	3.9	75
686	Streamlining primary and secondary care management pathways for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , 2017 , 38, 2980-2982	9.5	9
685	Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 209-218	7	124
684	Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart	7	29
683	Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the Heart GLORIA-AF Phase II Registry. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2376-2380	7	65
682	Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2261-2266	7	40
681	Bleeding Complications in Anticoagulated Patients With Atrial Fibrillation and Sepsis: A Propensity-Weighted Cohort Study. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	2
680	Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1072-1082	7	102
679	Hypertension and cardiac arrhythmias. <i>European Heart Journal</i> , 2017 , 38, 223-225	9.5	1
678	Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <i>BMJ, The</i> , 2017 , 356, j510	5.9	215
677	Sex-Related Differences in the Clinical Events of Patients With Atrial Fibrillation - The Fushimi AF Registry. <i>Circulation Journal</i> , 2017 , 81, 1403-1410	2.9	12

676	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017 , 38, 1710-1716	9.5	38
675	Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study. <i>PLoS ONE</i> , 2017 , 12, e0189495	3.7	58
674	Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017 , 8, 109703-109711	3.3	14
673	Stroke prevention in Atrial Fibrillation. <i>European Heart Journal</i> , 2017 , 38, 4-5	9.5	7
672	Cardiovascular Disorders 2017 , 403-436		
671	'Real-world' atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. <i>Europace</i> , 2017 , 19, 722-733	3.9	49
670	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016 , 37, 2893-2962	9.5	4465
669	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016 , 18, 1609-1678	3.9	1293
668	Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 42, 535-44	5.1	15
667	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2016 , 37, 2768-2801	9.5	1249
666	Optimizing stroke prevention in elderly patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 2121-2123	15.4	5
665	Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. <i>Lancet, The</i> , 2016 , 388, 1995-2003	4.0	173
664	Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etxilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. <i>Clinical Cardiology</i> , 2016 , 39, 555-564	3.3	58
663	Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. <i>American Heart Journal</i> , 2016 , 181, 83-91	4.9	22
662	Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States. <i>International Journal of Clinical Practice</i> , 2016 , 70, 752-63	2.9	85
661	Stroke prevention in atrial fibrillation. <i>Lancet, The</i> , 2016 , 388, 806-17	4.0	228
660	Drug-drug interactions of non-vitamin K oral anticoagulants. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 1445-1461	5.5	24
659	Response by Nielsen and Lip to Letter Regarding Article, "Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated? Yes: Even 1 Stroke Risk Factor Confers a Real Risk of Stroke". <i>Circulation</i> , 2016 , 134, e389-e390	16.7	

658	International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	14
657	Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?. <i>Circulation Journal</i> , 2016 , 80, 2102-8	2.9	12
656	Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study. <i>Stroke</i> , 2016 , 47, 2462-9	6.7	55
655	Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1452-1464	15.1	80
654	Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	141
653	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. <i>New England Journal of Medicine</i> , 2016 , 375, 2423-2434	59.2	929
652	Effects of Aspirin on Endothelial Function and Hypertension. <i>Current Hypertension Reports</i> , 2016 , 18, 83	4.7	28
651	Atrial fibrillation. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16016	51.1	115
650	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2016 , 6, 30060	4.9	21
649	Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives. <i>Europace</i> , 2016 , 18, 1507-1513	3.9	7
648	Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark. <i>Scientific Reports</i> , 2016 , 6, 31477	4.9	68
647	Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2016 , 18, 1593-1598	3.9	12
646	Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. <i>Scientific Reports</i> , 2016 , 6, 27410	4.9	48
645	Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <i>BMJ, The</i> , 2016 , 353, i3189	5.9	280
644	Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 1056-63	7	27
643	Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 975-986	7	190
642	Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies. <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 88, E12-22	2.7	17
641	Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study. <i>Clinical Research in Cardiology</i> , 2016 , 105, 912-920	6.1	47

640	Associations of retinal artery occlusion and retinal vein occlusion to mortality, stroke, and myocardial infarction: a systematic review. <i>Eye</i> , 2016 , 30, 1031-8	4.4	29
639	Letter by Nielsen et al Regarding Article, "Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis". <i>Stroke</i> , 2016 , 47, e193	6.7	
638	Epidemiology and pathogenesis of diffuse obstructive coronary artery disease: the role of arterial stiffness, shear stress, monocyte subsets and circulating microparticles. <i>Annals of Medicine</i> , 2016 , 48, 444-455	1.5	16
637	Response. <i>Chest</i> , 2016 , 149, 1590-1	5.3	
636	Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. <i>EBioMedicine</i> , 2016 , 8, 309-316	8.8	28
635	Net Clinical Benefit of Edoxaban for Stroke, Mortality, and Bleeding Risk: Modeling Projections for a European Population. <i>JACC: Clinical Electrophysiology</i> , 2016 , 2, 47-54	4.6	2
634	Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials). <i>American Journal of Cardiology</i> , 2016 , 118, 72-8	3	21
633	A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme. <i>Europace</i> , 2016 , 18, 1779-1786	3.9	41
632	Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation: The Chinese Atrial Fibrillation Registry Study. <i>Stroke</i> , 2016 , 47, 1803-10	6.7	62
631	Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. <i>Europace</i> , 2016 , 18, 1308-18	3.9	42
630	Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1247.e23-1247.e28	3.8	16
629	Relation of female sex to left atrial diameter and cardiovascular death in atrial fibrillation: The AFFIRM Trial. <i>International Journal of Cardiology</i> , 2016 , 207, 258-63	3.2	30
628	βBlockers in Atrial Fibrillation Patients With or Without Heart Failure: Association With Mortality in a Nationwide Cohort Study. <i>Circulation: Heart Failure</i> , 2016 , 9, e002597	7.6	37
627	Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. <i>International Journal of Stroke</i> , 2016 , 11, 302-12	6.3	52
626	Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. <i>International Journal of Cardiology</i> , 2016 , 204, 88-94	3.2	62
625	The SAME-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 177-87	2.5	15
624	Recalibration of the HAS-BLED Score: Should Hemorrhagic Stroke Account for One or Two Points?. <i>Chest</i> , 2016 , 149, 311-314	5.3	9
623	EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. <i>European Heart Journal Cardiovascular Imaging</i> , 2016 , 17, 355-83	4.1	170

622	From clinical trials to real-world clinical practice: observations on the direct oral anticoagulants. <i>Lancet Haematology</i> , 2016, 3, e2-3	14.6	1
621	'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry. <i>Europace</i> , 2016, 18, 648-57	3.9	45
620	Diabetes mellitus and risk of ischemic stroke in patients with heart failure and no atrial fibrillation. <i>International Journal of Cardiology</i> , 2016, 209, 1-6	3.2	12
619	Atrial Fibrillation and Stroke: Making Sense of Recent Observations on Anticoagulation. <i>Cardiology Clinics</i> , 2016, 34, 317-28	2.5	5
618	Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 233-44	5.1	2
617	Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. <i>Heart Failure Clinics</i> , 2016, 12, 257-71	3.3	5
616	Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage. <i>Circulation</i> , 2016, 133, 1540-7	16.7	83
615	Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. <i>Clinical Research in Cardiology</i> , 2016, 105, 412-20	6.1	58
614	Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation: The AMADEUS Trial. <i>Stroke</i> , 2016, 47, 523-6	6.7	31
613	From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. <i>Journal of Human Hypertension</i> , 2016, 30, 463-6	2.6	52
612	Preventing Thrombosis to Improve Outcomes in Heart Failure Patients. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 386-92	8.5	4
611	Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. <i>American Journal of Medicine</i> , 2016, 129, 600-7	2.4	75
610	Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention. <i>F1000Research</i> , 2016, 5, 2887	3.6	3
609	Association of Smoking, Alcohol, and Obesity with Cardiovascular Death and Ischemic Stroke in Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study and Cardiovascular Health Study (CHS). <i>PLoS ONE</i> , 2016, 11, e0147065	3.7	32
608	Use of the SAME-TT2R2 Score to Predict Good Anticoagulation Control with Warfarin in Chinese Patients with Atrial Fibrillation: Relationship to Ischemic Stroke Incidence. <i>PLoS ONE</i> , 2016, 11, e0150674	2.7	30
607	Vascular Disease and Risk Stratification for Ischemic Stroke and All-Cause Death in Heart Failure Patients without Diagnosed Atrial Fibrillation: A Nationwide Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0152269	2.7	6
606	Atrial Fibrillation and Heart Failure: How Should We Manage Our Patients?. <i>Arrhythmia and Electrophysiology Review</i> , 2016, 5, 162-163	3.2	1
605	miRNA-197 and miRNA-223 and cardiovascular death in coronary artery disease patients. <i>Annals of Translational Medicine</i> , 2016, 4, 200	3.2	6

604	Authors' reply to Beales. <i>BMJ, The</i> , 2016 , 532, i266	5.9	
603	Editors' Choice 2015 papers in Thrombosis and Haemostasis. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 230-2	7	0
602	Altered fibrin clot structure in patients with atrial fibrillation and worsening renal function. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 408-9	7	5
601	Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias: Endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca Rítmica (SOLAECE). <i>Thrombosis and Haemostasis</i> , 2016 , 116, 210-221	3.2	3
600	Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial fibrillation. An analysis of 425,600 Chinese individuals without prior stroke. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 184-92	7	17
599	Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses. <i>PLoS ONE</i> , 2016 , 11, e0157129	3.7	4
598	Determinants and Time Trends for Ischaemic and Haemorrhagic Stroke in a Large Chinese Population. <i>PLoS ONE</i> , 2016 , 11, e0163171	3.7	2
597	Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 1711-4	15.4	77
596	Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 1236-1244	2.6	50
595	Difficult situations in anticoagulation after stroke: between Scylla and Charybdis. <i>Current Opinion in Neurology</i> , 2016 , 29, 42-8	7.1	4
594	EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. <i>Europace</i> , 2016 , 18, 1455-1490	3.9	268
593	Dabigatran in clinical practice: Contemporary overview of the evidence. <i>International Journal of Cardiology</i> , 2016 , 220, 417-28	3.2	6
592	Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom. <i>Heart</i> , 2016 , 102, 1878-1882	5.1	15
591	Rationale and design of the Chinese Atrial Fibrillation Registry Study. <i>BMC Cardiovascular Disorders</i> , 2016 , 16, 130	2.3	37
590	Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: The Beijing PLA Hospital Atrial Fibrillation Project. <i>Scientific Reports</i> , 2016 , 6, 31755	4.9	18
589	Premature Cardiac Aging in South Asian Compared to Afro-Caribbean Subjects in a Community-Based Screening Study. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	3
588	Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. <i>Scientific Reports</i> , 2016 , 6, 30271	4.9	35
587	Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2016 , 6, 19188	4.9	38

586	Stroke prevention in atrial fibrillation and 'real world' adherence to guidelines in the Balkan Region: The BALKAN-AF Survey. <i>Scientific Reports</i> , 2016 , 6, 20432	4.9	31
585	IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosis in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. <i>BMJ Open</i> , 2016 , 6, e012241	3	10
584	Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. <i>Scientific Reports</i> , 2016 , 6, 24376	4.9	40
583	Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study. <i>Heart Rhythm</i> , 2016 , 13, 1581-8	6.7	29
582	How to Manage Occult Atrial Fibrillation Detected on Long-Term Monitoring. <i>Circulation</i> , 2016 , 133, 1290-5	6.7	7
581	Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?. <i>Stroke</i> , 2016 , 47, 1831-6	6.7	47
580	Clinical Characteristics and Outcomes in Extreme Elderly (Age ≥85 Years) Japanese Patients With Atrial Fibrillation: The Fushimi AF Registry. <i>Chest</i> , 2016 , 149, 401-412	5.3	68
579	Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). <i>American Heart Journal</i> , 2016 , 178, 126-34	4.9	95
578	Evaluation of a 'color coding' system for the assessment of patients undergoing primary percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2016 , 212, 371-6	3.2	3
577	Relation of the SAME-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials. <i>International Journal of Cardiology</i> , 2016 , 216, 168-72	3.2	14
576	Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range Observations from the SPORTIF Trials. <i>American Journal of Medicine</i> , 2016 , 129, 1110-6	2.4	17
575	Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project. <i>Chest</i> , 2016 , 149, 960-8	5.3	43
574	Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated? Yes: Even 1 Stroke Risk Factor Confers a Real Risk of Stroke. <i>Circulation</i> , 2016 , 133, 1498-503; discussion 1503	16.7	28
573	Impact on Outcomes of Changing Treatment Guideline Recommendations for Stroke Prevention in Atrial Fibrillation: A Nationwide Cohort Study. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 567-74	6.4	23
572	Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2016 , 1, 172-80	16.2	93
571	Effect of renal function on whole blood and fibrin clot formation in atrial fibrillation patients on warfarin. <i>Annals of Medicine</i> , 2016 , 48, 275-81	1.5	2
570	Carotid Atherosclerosis and Stroke in Atrial Fibrillation: The Atherosclerosis Risk in Communities Study. <i>Stroke</i> , 2016 , 47, 1643-6	6.7	24
569	Female Sex, Time in Therapeutic Range, and Clinical Outcomes in Atrial Fibrillation Patients Taking Warfarin. <i>Stroke</i> , 2016 , 47, 1665-8	6.7	28

568	EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication. <i>Journal of Arrhythmia</i> , 2016 , 32, 247-78	1.5	59
567	Echocardiographic Structure and Function in Hypertensive Disorders of Pregnancy: A Systematic Review. <i>Circulation: Cardiovascular Imaging</i> , 2016 , 9,	3.9	50
566	Determinants of Time in Therapeutic Range in Patients Receiving Oral Anticoagulants (A Substudy of IMPACT). <i>American Journal of Cardiology</i> , 2016 , 118, 1680-1684	3	15
565	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016 , 50, e1-e88	3	589
564	Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2-VASc Score of 1 (Men) or 2 (Women)?. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	16
563	Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study. <i>Stroke</i> , 2016 , 47, 2707-2713	6.7	28
562	Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2033-47	4	4
561	Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism. <i>Heart</i> , 2016 , 102, 975-83	5.1	8
560	Causes of Death and Influencing Factors in Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2016 , 129, 1278-1287	2.4	90
559	CHA DS -VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. <i>European Journal of Heart Failure</i> , 2016 , 18, 1261-1266	12.3	21
558	Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial. <i>International Journal of Cardiology</i> , 2016 , 221, 379-82	3.2	15
557	A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation. <i>Journal of Internal Medicine</i> , 2016 , 279, 467-76	10.8	8
556	Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. <i>Journal of Internal Medicine</i> , 2015 , 278, 1-18	10.8	53
555	Comparaci3n de las ecuaciones de filtrado glomerular estimado para determinar la posolog3a de los nuevos anticoagulantes orales para pacientes con fibrilaci3n auricular. <i>Revista Espanola De Cardiologia</i> , 2015 , 68, 497-504	1.5	27
554	Development of recommendations to continue anticoagulation with one of the two types of oral anticoagulants based on the identification of patients' preference. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 166-77	5.3	9
553	Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 146-53	5.3	14
552	144 Does Home-Based, Slow Deep Breathing Training Reduce Central Sympathetic Outflow and Enhance Baroreflex Sensitivity in Primary Hypertension?. <i>Heart</i> , 2015 , 101, A83.1-A83	5.1	1
551	Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. <i>American Journal of Medicine</i> , 2015 , 128, 1306-13.e1	2.4	118

550	Recurrent Stroke: The Value of the CHA2DS2VASc Score and the Essen Stroke Risk Score in a Nationwide Stroke Cohort. <i>Stroke</i> , 2015 , 46, 2491-7	6.7	25
549	Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF). <i>American Heart Journal</i> , 2015 , 169, 464-71.e2	4.9	17
548	Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation: AMADEUS Trial. <i>Stroke</i> , 2015 , 46, 2523-8	6.7	43
547	Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. <i>European Heart Journal</i> , 2015 , 36, 1660-8	9.5	234
546	Atrial flutter and thromboembolic risk: a systematic review. <i>Heart</i> , 2015 , 101, 1446-55	5.1	41
545	Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. <i>Age and Ageing</i> , 2015 , 44, 874-8	3	51
544	Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project. <i>European Heart Journal</i> , 2015 , 36, 1822-30	9.5	37
543	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2015 , 17, 1169-86	3.9	89
542	Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk. <i>Progress in Cardiovascular Diseases</i> , 2015 , 58, 177-94	8.5	26
541	Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide Cohort Study. <i>Stroke</i> , 2015 , 46, 2168-74	6.7	56
540	The SAME-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective 'Real-world' Inception Cohort Study. <i>American Journal of Medicine</i> , 2015 , 128, 1237-43	2.4	42
539	The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: A systemic review and meta-analysis. <i>International Journal of Cardiology</i> , 2015 , 195, 237-42	3.2	22
538	Switching from a vitamin K antagonist to a NOAC. <i>Lancet Haematology</i> , 2015 , 2, e132-3	14.6	2
537	Free Light Chains in patients with acute coronary syndromes: Relationships to inflammation and renal function. <i>International Journal of Cardiology</i> , 2015 , 185, 322-7	3.2	6
536	Ethnic differences in the diurnal variation of symptom onset time for acute ST elevation myocardial infarction - An observational cohort study. <i>International Journal of Cardiology</i> , 2015 , 187, 414-6	3.2	1
535	Small-size Microparticles as Indicators of Acute Decompensated State in Ischemic Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015 , 68, 951-8	0.7	4
534	Simultaneous computerised activation of the primary percutaneous coronary intervention pathway reduces out-of-hours door-to-balloon time but not mortality. <i>International Journal of Cardiology</i> , 2015 , 186, 226-30	3.2	
533	Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study. <i>Chest</i> , 2015 , 147, 1651-1658	5.3	35

532	Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2015 , 350, h1618	5.9	218
531	Changes in renal function after catheter ablation of atrial fibrillation are associated with CHADS2 and CHA2DS2-VASc scores and arrhythmia recurrences. <i>Heart</i> , 2015 , 101, 126-31	5.1	23
530	A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UnderRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. <i>American Heart Journal</i> , 2015 , 169, 597-604.e5	4.9	30
529	Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1385-94	15.1	115
528	Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 937-48	5.5	4
527	Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. <i>European Journal of Heart Failure</i> , 2015 , 17, 570-82	12.3	54
526	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. <i>Clinical Research in Cardiology</i> , 2015 , 104, 418-29	6.1	77
525	Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2015 , 13, 1155-63	2.5	1
524	Leukoaraiosis and stroke recurrence risk in patients with and without atrial fibrillation. <i>Neurology</i> , 2015 , 84, 1213-9	6.5	28
523	Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. <i>Europace</i> , 2015 , 17, 1777-86	3.9	103
522	Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: AMADEUS Trial. <i>Stroke</i> , 2015 , 46, 3202-7	6.7	10
521	Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis. <i>Stroke</i> , 2015 , 46, 2555-61	6.7	141
520	Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1339-47	15.1	92
519	Intracerebral haemorrhage, atrial fibrillation, and anticoagulation. <i>Lancet, The</i> , 2015 , 386, 1736-7	4.0	2
518	Patients With Ischemic Stroke and Incident Atrial Fibrillation: A Nationwide Cohort Study. <i>Stroke</i> , 2015 , 46, 2432-7	6.7	56
517	Development and validation of a new assay for assessing clot integrity. <i>Vascular Pharmacology</i> , 2015 , 71, 102-7	5.9	6
516	Cardiac Fibrosis in Patients With Atrial Fibrillation: Mechanisms and Clinical Implications. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 943-59	15.1	299
515	Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 1030-8	27.4	192

514	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015 , 17, 1467-507	3.9	803
513	Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. <i>Stroke</i> , 2015 , 46, 2830-7	6.7	5
512	Sex differences in clinical characteristics and inpatient outcomes among 2442 hospitalized Chinese patients with nonvalvular atrial fibrillation: The Nanchang Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , 2015 , 201, 195-9	3.2	5
511	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. <i>BMJ, The</i> , 2015 , 351, h4451	5.9	172
510	Assessing Eligibility for Anticoagulation After Diagnosis of Atrial Fibrillation--Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 949-50	27.4	1
509	Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015 , 68, 497-504	0.7	11
508	Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2661-78	4	2
507	Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis. <i>International Journal of Cardiology</i> , 2015 , 181, 247-54	3.2	5
506	Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. <i>Stroke</i> , 2015 , 46, 23-30	6.7	75
505	Atrial fibrillation patients categorized as "not for anticoagulation" according to the 2014 Canadian Cardiovascular Society algorithm are not "low risk". <i>Canadian Journal of Cardiology</i> , 2015 , 31, 24-8	3.8	13
504	Stroke and major bleeding risk in elderly patients aged ≥5 years with atrial fibrillation: the Loire Valley atrial fibrillation project. <i>Stroke</i> , 2015 , 46, 143-50	6.7	95
503	Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 7-20	4.1	19
502	Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. <i>Europace</i> , 2015 , 17, 24-31	3.9	113
501	Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study. <i>International Journal of Cardiology</i> , 2015 , 201, 693-8	3.2	13
500	The impact of associated diabetic retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrillation: the loire valley atrial fibrillation project. <i>Chest</i> , 2015 , 147, 1103-1110	5.3	21
499	Influence of age on respiratory modulation of muscle sympathetic nerve activity, blood pressure and baroreflex function in humans. <i>Experimental Physiology</i> , 2015 , 100, 1039-51	2.4	13
498	Age-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe: The EORP-AF General Pilot Registry (EURObservational Research Programme-Atrial Fibrillation). <i>JACC: Clinical Electrophysiology</i> , 2015 , 1, 326-334	4.6	37
497	Benefit of Anticoagulation Therapy in Hyperthyroidism-Related Atrial Fibrillation. <i>Clinical Cardiology</i> , 2015 , 38, 476-82	3.3	18

496	Optimising stroke prevention in patients with atrial fibrillation. <i>British Journal of General Practice</i> , 2015 , 65, 117	1.6	3
495	Efficacy and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in Japanese patients with atrial fibrillation [meta-analysis]. <i>Circulation Journal</i> , 2015 , 79, 339-45	2.9	30
494	A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. <i>Scientific Reports</i> , 2015 , 5, 9902	4.9	109
493	Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. <i>British Journal of General Practice</i> , 2015 , 65, e16-23	1.6	31
492	Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. <i>Chest</i> , 2015 , 148, 62-72	5.3	33
491	Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1362-73	3.8	4
490	Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. <i>International Journal of Clinical Practice</i> , 2015 , 69, 1341-8	2.9	13
489	Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 403-9	7	11
488	Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 1370-7	7	102
487	Thromboembolic risk stratification of patients hospitalized with heart failure in sinus rhythm: a nationwide cohort study. <i>European Journal of Heart Failure</i> , 2015 , 17, 828-36	12.3	28
486	Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. <i>European Journal of Heart Failure</i> , 2015 , 17, 1192-200	12.3	82
485	A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2). <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 1105-13	15.4	9
484	Safety and efficacy of abciximab in older adults undergoing percutaneous coronary intervention. <i>International Journal of Clinical Practice</i> , 2015 , 69, 1334-40	2.9	
483	The Clinical Relevance of Microbleeds in Stroke study (CROMIS-2): rationale, design, and methods. <i>International Journal of Stroke</i> , 2015 , 10 Suppl A100, 155-61	6.3	44
482	Stroke in atrial fibrillation and improving the identification of 'high-risk' patients: the crossroads of immunity and thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 1968-70	15.4	9
481	European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>European Journal of Heart Failure</i> , 2015 , 17, 848-74	12.3	27
480	Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 2130-2	15.4	3
479	Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 617-24	7	38

478	Renal Impairment and Prognosis of Patients with Atrial Fibrillation Undergoing Coronary Intervention - The AFCAS Trial. <i>PLoS ONE</i> , 2015 , 10, e0128492	3.7	7
477	Predictors for Stroke and Death in Non-Anticoagulated Asian Patients with Atrial Fibrillation: The Fushimi AF Registry. <i>PLoS ONE</i> , 2015 , 10, e0142394	3.7	23
476	Risk of Ischemic Stroke after Intracranial Hemorrhage in Patients with Atrial Fibrillation. <i>PLoS ONE</i> , 2015 , 10, e0145579	3.7	12
475	Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 826-34	7	77
474	Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015 , 22, 610-7	4	15
473	Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany. <i>BioMed Research International</i> , 2015 , 2015, 876923	3	16
472	Asymptomatic versus symptomatic atrial fibrillation: A systematic review of age/gender differences and cardiovascular outcomes. <i>International Journal of Cardiology</i> , 2015 , 191, 172-7	3.2	91
471	Stroke prevention in atrial fibrillation: a systematic review. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1950-62	27.4	187
470	Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. <i>Europace</i> , 2015 , 17, 1215-22	3.9	27
469	Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. <i>Circulation</i> , 2015 , 132, 517-25	16.7	189
468	Gender differences in stroke prevention in atrial fibrillation in general practice: using the GRASP-AF audit tool. <i>International Journal of Clinical Practice</i> , 2015 , 69, 840-5	2.9	17
467	Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardiac (SLAE) [SOLAE]. <i>Europace</i> , 2015 , 17, 1717-18	3.9	94
466	Incidence of Stroke or Systemic Embolism in Paroxysmal Versus Sustained Atrial Fibrillation: The Fushimi Atrial Fibrillation Registry. <i>Stroke</i> , 2015 , 46, 3354-61	6.7	75
465	Blood pressure and prognosis in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. <i>Clinical Research in Cardiology</i> , 2015 , 104, 1088-96	6.1	27
464	Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. <i>BMJ, The</i> , 2015 , 351, h5876	5.9	91
463	Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. <i>Chest</i> , 2015 , 147, 109-119	5.3	161
462	Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. <i>European Heart Journal</i> , 2015 , 36, 653-6	9.5	41
461	Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. <i>European Heart Journal</i> , 2015 , 36, 297-306	9.5	108

460	Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation. <i>Current Treatment Options in Neurology</i> , 2015 , 17, 331	4.4	1
459	Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 635-42	15.1	187
458	Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. <i>International Journal of Cardiology</i> , 2015 , 180, 246-54	3.2	113
457	Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. <i>American Journal of Medicine</i> , 2015 , 128, 509-18.e2	2.4	166
456	Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 45-62	4.1	5
455	Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2015 , 17, 194-206	3.9	30
454	Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?. <i>Trends in Cardiovascular Medicine</i> , 2015 , 25, 315-36	6.9	15
453	Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 495-504	15.4	110
452	The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. <i>PLoS ONE</i> , 2015 , 10, e0122520	3.7	52
451	Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study. <i>PLoS ONE</i> , 2015 , 10, e0125257	3.7	20
450	Monitoring the Effects and Antidotes of the Non-vitamin K Oral Anticoagulants. <i>Arrhythmia and Electrophysiology Review</i> , 2015 , 4, 90-5	3.2	2
449	Can venous thromboembolism navigate the prevention of cardiovascular complications?. <i>Annals of Translational Medicine</i> , 2015 , 3, 116	3.2	
448	Best practice for atrial fibrillation patient education. <i>Current Pharmaceutical Design</i> , 2015 , 21, 533-43	3.3	45
447	A comprehensive insight of novel antioxidant therapies for atrial fibrillation management. <i>Drug Metabolism Reviews</i> , 2015 , 47, 388-400	7	10
446	Editors' Choice papers in Thrombosis and Haemostasis. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 217-20	7	
445	Patterns in atrial fibrillation management and Real-world Adherence to guidelines in the Balkan Region: an overview of the Balkan Atrial fibrillation survey. <i>European Heart Journal</i> , 2015 , 36, 1943-4	9.5	8
444	Warfarin or novel oral anticoagulants for atrial fibrillation?. <i>Lancet, The</i> , 2014 , 383, 931-3	4.0	20
443	Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. <i>American Journal of Medicine</i> , 2014 , 127, 329-336.e4	2.4	56

442	Left ventricular geometry and outcomes in patients with atrial fibrillation: the AFFIRM Trial. <i>International Journal of Cardiology</i> , 2014 , 170, 303-8	3.2	25
441	Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. <i>American Journal of Medicine</i> , 2014 , 127, 650-656.e5	2.4	88
440	Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. <i>American Heart Journal</i> , 2014 , 167, 329-34	4.9	85
439	Edoxaban: a focused review of its clinical pharmacology. <i>European Heart Journal</i> , 2014 , 35, 1844-55	9.5	90
438	'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey. <i>American Journal of Medicine</i> , 2014 , 127, 519-29.e1	2.4	123
437	Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. <i>Circulation</i> , 2014 , 129, 1577-85	16.7	204
436	A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2014 , 16, 308-19	3.9	224
435	Comparison of clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation. <i>Stroke</i> , 2014 , 45, 426-31	6.7	23
434	Antithrombotic and anticoagulant therapy for atrial fibrillation. <i>Cardiology Clinics</i> , 2014 , 32, 585-99	2.5	5
433	New advances in the treatment of atrial fibrillation: focus on stroke prevention. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 2193-204	4	3
432	Small-size platelet microparticles trigger platelet and monocyte functionality and modulate thrombogenesis via P-selectin. <i>British Journal of Haematology</i> , 2014 , 166, 571-80	4.5	19
431	Efficacy of Ib blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. <i>Lancet, The</i> , 2014 , 384, 2235-43	40	323
430	Statin treatment is associated with improved prognosis in patients with AF-related stroke. <i>International Journal of Cardiology</i> , 2014 , 177, 129-33	3.2	24
429	Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project. <i>American Journal of Medicine</i> , 2014 , 127, 972-8	2.4	41
428	Exercise-induced changes in inflammatory processes: Implications for thrombogenesis in cardiovascular disease. <i>Annals of Medicine</i> , 2014 , 46, 439-55	1.5	40
427	Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?. <i>Journal of the American Heart Association</i> , 2014 , 3,	6	33
426	Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1658-65	15.1	136
425	The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: a systematic review. <i>Clinical Therapeutics</i> , 2014 , 36, 1135-44	3.5	42

424	New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. <i>Journal of the American Geriatrics Society</i> , 2014 , 62, 857-64	5.6	167
423	Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study. <i>Stroke</i> , 2014 , 45, 2127-30	6.7	10
422	Use of novel oral anticoagulants in patients with heart failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014 , 16, 285	2.1	4
421	Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. <i>Heart Rhythm</i> , 2014 , 11, 1752-9	6.7	60
420	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>Europace</i> , 2014 , 16, 1655-73	3.9	77
419	Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong. <i>Heart Rhythm</i> , 2014 , 11, 1401-8	6.7	86
418	Patent foramen ovale and migraine attacks: a systematic review. <i>American Journal of Medicine</i> , 2014 , 127, 411-20	2.4	50
417	Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. <i>Clinical Therapeutics</i> , 2014 , 36, 192-210.e20	3.5	62
416	Common Questions in Anticoagulation Management in Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2014 , 6, 79-86	1.4	1
415	Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study). <i>American Journal of Cardiology</i> , 2014 , 113, 480-4	3	19
414	Early management of atrial fibrillation to prevent cardiovascular complications. <i>European Heart Journal</i> , 2014 , 35, 1448-56	9.5	128
413	Ventricular-arterial coupling in obstructive sleep apnea. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 624-9		6
412	SAME-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. <i>American Journal of Medicine</i> , 2014 , 127, 1083-1088	2.4	94
411	My Approach to the use of NOACs for stroke prevention in patients with atrial fibrillation. <i>Trends in Cardiovascular Medicine</i> , 2014 , 24, 265-6	6.9	1
410	Impact of non-vitamin k antagonist oral anticoagulants on intracranial bleeding in Asian patients with non-valvular atrial fibrillation. <i>Circulation Journal</i> , 2014 , 78, 2367-72	2.9	36
409	Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 549-56	7	17
408	Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 981-8	7	77
407	Bare-metal vs. drug-eluting stents in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Circulation Journal</i> , 2014 , 78, 2674-81	2.9	19

406	Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS ₂ , CHA ₂ DS ₂ -VASc, R ₂ CHADS ₂ , HAS-BLED, ATRIA, and more). <i>Clinical Cardiology</i> , 2014 , 37, 634-44	3.3	35
405	Stroke prevention in atrial fibrillation: an Asian perspective. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 789-97		181
404	A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. <i>Chest</i> , 2014 , 145, 1370-1382	5.3	54
403	Non-vitamin K antagonist oral anticoagulants: an appeal for consensus on terminology. <i>Chest</i> , 2014 , 145, 1177-1178	5.3	15
402	Response. <i>Chest</i> , 2014 , 145, 188-189	5.3	2
401	The impact of smoking on thromboembolism and mortality in patients with incident atrial fibrillation: insights from the Danish Diet, Cancer, and Health study. <i>Chest</i> , 2014 , 145, 559-66	5.3	40
400	The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide cohort study. <i>Chest</i> , 2014 , 146, 1337-1346	5.3	29
399	Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria. <i>PLoS ONE</i> , 2014 , 9, e99276	3.7	27
398	Cognitive function in ambulatory patients with systolic heart failure: insights from the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial. <i>PLoS ONE</i> , 2014 , 9, e113447	3.7	14
397	Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. <i>PLoS ONE</i> , 2014 , 9, e114445	3.7	46
396	Stroke and bleeding risk in atrial fibrillation. <i>Korean Circulation Journal</i> , 2014 , 44, 281-90	2.2	29
395	Circulating microparticles: challenges and perspectives of flow cytometric assessment. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 1009-14	7	49
394	Rhythm outcomes after catheter ablation of atrial fibrillation. Clinical implication of biomarkers. <i>Hamostaseologie</i> , 2014 , 34, 9-19	1.9	7
393	Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014 , 107, 955-67	2.7	97
392	Prognostic value of two polymorphisms in non-sarcomeric genes for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014 , 107, 613-21	2.7	9
391	Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. <i>European Heart Journal</i> , 2014 , 35, 1897-906	9.5	64
390	Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation. <i>Stroke</i> , 2014 , 45, 696-701	6.7	32
389	Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer. <i>British Journal of Cancer</i> , 2014 , 111, 1742-9	8.7	7

388	Assess bleeding risk with HAS-BLED and assess stroke risk with CHA2DS2-VASc in patients with atrial fibrillation. <i>Hypertension Research</i> , 2014 , 37, 699-700	4.7	1
387	Response. <i>Chest</i> , 2014 , 145, 419-420	5.3	1
386	Hormone replacement therapy and adverse outcomes in women with atrial fibrillation: an analysis from the atrial fibrillation follow-up investigation of rhythm management trial. <i>Stroke</i> , 2014 , 45, 3076-9	6.7	12
385	Relationship of the SAME-TTBB score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. <i>Chest</i> , 2014 , 146, 719-726	5.3	87
384	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?. <i>Hospital Practice (1995)</i> , 2014 , 42, 153-62	2.2	1
383	Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). <i>European Heart Journal</i> , 2014 , 35, 3365-76	9.5	161
382	Vernakalant hydrochloride to treat atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 865-72	4	1
381	One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry. <i>Clinical Cardiology</i> , 2014 , 37, 357-64	3.3	76
380	Predictive value of atrial high-rate episodes for arterial stiffness and endothelial dysfunction in dual-chamber pacemaker patients. <i>European Journal of Clinical Investigation</i> , 2014 , 44, 13-21	4.6	3
379	Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2471-82	15.1	205
378	Age dependence of risk factors for stroke and death in young patients with atrial fibrillation: a nationwide study. <i>Stroke</i> , 2014 , 45, 1331-7	6.7	17
377	Safety of new oral anticoagulant drugs: a perspective. <i>Therapeutic Advances in Drug Safety</i> , 2014 , 5, 8-20	3.5	45
376	Integrating real-time clinical information to provide estimates of net clinical benefit of antithrombotic therapy for patients with atrial fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 680-6	5.8	17
375	Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 933-42	7	82
374	Potential value of targeting von Willebrand factor in atherosclerotic cardiovascular disease. <i>Expert Opinion on Therapeutic Targets</i> , 2014 , 18, 43-53	6.4	18
373	Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. <i>American Journal of Medicine</i> , 2014 , 127, 979-986.e2	2.4	26
372	Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease. <i>PLoS ONE</i> , 2014 , 9, e94420	3.7	31
371	Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons. <i>PLoS ONE</i> , 2014 , 9, e100478	3.7	20

370	The association of CHA2DS2-VASc score and blood biomarkers with ischemic stroke outcomes: the Belgrade stroke study. <i>PLoS ONE</i> , 2014 , 9, e106439	3.7	14
369	Effects of radiofrequency catheter ablation of atrial fibrillation on soluble P-selectin, von Willebrand factor and IL-6 in the peripheral and cardiac circulation. <i>PLoS ONE</i> , 2014 , 9, e111760	3.7	10
368	The Potential Role of Edoxaban in Stroke Prevention Guidelines. <i>Arrhythmia and Electrophysiology Review</i> , 2014 , 3, 40-3	3.2	1
367	Management of Atrial Fibrillation in Patients With Kidney Disease. <i>Journal of Atrial Fibrillation</i> , 2014 , 6, 989	0.8	
366	Stroke And Bleeding Risk Assessment: Where Are We Now?. <i>Journal of Atrial Fibrillation</i> , 2014 , 6, 1042	0.8	0
365	Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?. <i>Current Vascular Pharmacology</i> , 2014 , 12, 373-83	3.3	1
364	Rheumatoid arthritis and autonomic function (1132.10). <i>FASEB Journal</i> , 2014 , 28, 1132.10	0.9	
363	Reply: Dabigatran's 'real-world' data about risk of myocardial infarction and gastrointestinal bleeding contradicts with randomized trials. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 946-7	15.1	2
362	Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study. <i>International Journal of Cardiology</i> , 2013 , 168, 1832-6	3.2	31
361	Safety and efficacy of new anticoagulants in patients with heart failure. <i>Current Heart Failure Reports</i> , 2013 , 10, 18-25	2.8	3
360	Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation. <i>Drug Safety</i> , 2013 , 36, 93-100	15.0	8
359	Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). <i>American Journal of Cardiology</i> , 2013 , 111, 1159-64	3	91
358	Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke, in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study. <i>International Journal of Cardiology</i> , 2013 , 168, 414-9	3.2	52
357	Aspirin and aspirin resistance in coronary artery disease. <i>Current Opinion in Pharmacology</i> , 2013 , 13, 242-50	5.0	22
356	The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2199-204	15.1	144
355	Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants. <i>Pharmacoeconomics</i> , 2013 , 31, 971-80	4.4	32
354	The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study. <i>Catheterization and Cardiovascular Interventions</i> , 2013 , 82, E864-70	2.7	17
353	Atherosclerosis and thromboembolic risk in atrial fibrillation: focus on peripheral vascular disease. <i>Annals of Medicine</i> , 2013 , 45, 274-90	1.5	17

352	Antithrombotic Management and Type of Stent in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013 , 66, 12-16	0.7	
351	Stroke prevention in atrial fibrillation in heart failure. <i>Heart Failure Clinics</i> , 2013 , 9, 427-35, viii	3.3	2
350	Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 386-7	15.1	59
349	Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: would the novel oral anticoagulants have an impact?. <i>International Journal of Cardiology</i> , 2013 , 168, 515-22	3.2	31
348	Body mass index and adverse events in patients with incident atrial fibrillation. <i>American Journal of Medicine</i> , 2013 , 126, 640.e9-17	2.4	66
347	A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. <i>International Journal of Cardiology</i> , 2013 , 168, 4744-9	3.2	69
346	Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013 , 6, 31-8	6.4	20
345	Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. <i>Chest</i> , 2013 , 143, 179-184	5.3	143
344	Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 615-26	15.4	23
343	Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 981-9	15.1	265
342	Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2013 , 15, 1526-32	3.9	17
341	The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. <i>European Heart Journal</i> , 2013 , 34, 170-6	9.5	134
340	Current practice in Europe: how do we manage patients with ventricular tachycardia? European Heart Rhythm Association survey. <i>Europace</i> , 2013 , 15, 167-9	3.9	19
339	Current practice for diagnosis and management of silent atrial fibrillation: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2013 , 15, 1223-5	3.9	29
338	Atrial fibrillation as a risk factor for cognitive impairment: a semi-systematic review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013 , 106, 795-802	2.7	56
337	A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice. <i>Hospital Practice (1995)</i> , 2013 , 41, 61-70	2.2	
336	Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants. <i>Hospital Practice (1995)</i> , 2013 , 41, 71-8	2.2	3
335	Left atrial appendage occlusion for stroke prevention in atrial fibrillation in Europe: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2013 , 15, 141-3	3.9	22

334	Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. <i>European Heart Journal</i> , 2013 , 34, 3572-9	9.5	66
333	Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. <i>European Heart Journal</i> , 2013 , 34, 2746-51	9.5	638
332	Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade Atrial Fibrillation Study. <i>European Journal of Heart Failure</i> , 2013 , 15, 415-24	12.3	36
331	Warfarin for stroke prevention in atrial fibrillation: time to switch?. <i>International Journal of Clinical Practice</i> , 2013 , 67, 603-5	2.9	3
330	The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 975-87	15.4	34
329	Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 1619-29	2.5	12
328	Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 77-90	2.5	7
327	Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a 'real-world' community cohort of patients with atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 1032-8	4.6	28
326	Alcohol intake and prognosis of atrial fibrillation. <i>Heart</i> , 2013 , 99, 1093-9	5.1	45
325	Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?. <i>European Heart Journal</i> , 2013 , 34, 1041-9	9.5	108
324	Hospital delay in South Asian patients with acute ST-elevation myocardial infarction in the UK. <i>European Journal of Preventive Cardiology</i> , 2013 , 20, 737-42	3.9	20
323	Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillation--focus on the elderly. <i>Circulation Journal</i> , 2013 , 77, 1380-8	2.9	31
322	Receptors to interleukin-6 and adhesion molecules on circulating monocyte subsets in acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 340-8	7	5
321	Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 1189-98	7	139
320	Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 1074-9	7	80
319	Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 1087-107	7	278
318	Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 328-36	7	43
317	Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT ₂ C ₂ score. <i>Chest</i> , 2013 , 144, 1555-1563	5.3	347

316	Trace protein and prognosis in patients with atrial fibrillation receiving anticoagulation treatment. <i>Chest</i> , 2013 , 144, 1564-1570	5.3	12
315	Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study. <i>Chest</i> , 2013 , 144, 1839-1847	5.3	27
314	Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. <i>PLoS ONE</i> , 2013 , 8, e63479	3.7	297
313	Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 956-60	7	88
312	Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. <i>PLoS ONE</i> , 2013 , 8, e74037	3.7	131
311	Age as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications in Thromboprophylaxis in the Era of Novel Oral Anticoagulants. <i>Journal of Atrial Fibrillation</i> , 2013 , 6, 783	0.8	11
310	Influence of age on respiratory modulation of muscle sympathetic nerve activity and blood pressure in humans. <i>FASEB Journal</i> , 2013 , 27, 1118.23	0.9	
309	Heparin bridging vs. uninterrupted oral anticoagulation in patients with Atrial Fibrillation undergoing Coronary Artery Stenting. Results from the AFCAS registry. <i>Circulation Journal</i> , 2012 , 76, 1363-8	2.9	34
308	Stroke and thromboembolism in atrial fibrillation. <i>Circulation Journal</i> , 2012 , 76, 2289-304	2.9	100
307	Atrial fibrillation. <i>Lancet, The</i> , 2012 , 379, 648-61	4.0	287
306	Inflammation in atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2263-70	15.1	479
305	Comments on the Spanish Society of Cardiology Critical Review of the ESC 2010 Clinical Practice Guidelines on Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012 , 65, 390-391	0.7	
304	Stroke and bleeding in atrial fibrillation with chronic kidney disease. <i>New England Journal of Medicine</i> , 2012 , 367, 625-35	59.2	624
303	Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. <i>BMJ, The</i> , 2012 , 345, e7097	5.9	98
302	International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). <i>American Heart Journal</i> , 2012 , 163, 13-19.e1	4.9	152
301	High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation: a reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 2414-2415	15.4	3
300	Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis. <i>Drugs</i> , 2012 , 72, 1755-64	12.1	15
299	The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. <i>Chest</i> , 2012 , 142, 1489-1498	5.3	281

298	Insights from the RCPE UK Consensus Conference on approaching the comprehensive management of atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2012 , 10, 697-700	2.5	4
297	A proposal for new clinical concepts in the management of atrial fibrillation. <i>American Heart Journal</i> , 2012 , 164, 292-302.e1	4.9	39
296	New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1413-25	15.1	211
295	Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 861-7	15.1	265
294	Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM). <i>American Journal of Cardiology</i> , 2012 , 110, 1799-802	3	71
293	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. <i>European Heart Journal</i> , 2012 , 33, 2719-47	9.5	2638
292	Anticoagulation versus placebo for heart failure in sinus rhythm. <i>Cochrane Database of Systematic Reviews</i> , 2012 , CD003336		10
291	Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. <i>Circulation</i> , 2012 , 126, 860-5	16.7	259
290	Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 738-46	15.1	241
289	Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. <i>Thrombosis and Haemostasis</i> , 2012 , 107, 584-9	7	239
288	Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , 2012 , 141, e531S-e575S	5.3	763
287	Can we predict stroke in atrial fibrillation?. <i>Clinical Cardiology</i> , 2012 , 35 Suppl 1, 21-7	3.3	25
286	The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. <i>Thrombosis and Haemostasis</i> , 2012 , 107, 1172-9	7	326
285	Angiotensin receptor blockers and tumorigenesis: something to be (or not to be) concerned about?. <i>Current Hypertension Reports</i> , 2012 , 14, 183-92	4.7	3
284	Comparison of frequency of major adverse events in patients with atrial fibrillation receiving bare-metal versus drug-eluting stents in their coronary arteries. <i>American Journal of Cardiology</i> , 2012 , 110, 7-12	3	14
283	Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 459-66	6	53
282	Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012 , 5, 941-8	6.4	58
281	A contemporary view on endothelial function in heart failure. <i>European Journal of Heart Failure</i> , 2012 , 14, 873-81	12.3	46

280	Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>European Journal of Heart Failure</i> , 2012 , 14, 681-95	12.3	57
279	Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. <i>European Journal of Heart Failure</i> , 2012 , 14, 295-301	12.3	81
278	Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 1057-64	5.9	9
277	Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study. <i>European Journal of Heart Failure</i> , 2012 , 14, 211-8	12.3	46
276	Vascular ventricular coupling in patients with malignant phase hypertension: the West Birmingham malignant hypertension project. <i>Hypertension Research</i> , 2012 , 35, 725-8	4.7	2
275	Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. <i>European Heart Journal</i> , 2012 , 33, 1500-10	9.5	732
274	Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, and Health cohort study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012 , 5, 335-42	5.8	36
273	Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. <i>BMJ, The</i> , 2012 , 344, e3522	5.9	172
272	Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012 , 5, 312-8	6.4	93
271	Stroke Prevention in Atrial Fibrillation: Where are We Now?. <i>Clinical Medicine Insights: Cardiology</i> , 2012 , 6, 65-78	3.2	8
270	Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. <i>BMJ Open</i> , 2012 , 2,	3	40
269	Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. <i>BMJ Open</i> , 2012 , 2,	3	40
268	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2012 , 14, 8-27	3.9	156
267	Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort. <i>Europace</i> , 2012 , 14, 184-90	3.9	32
266	Periprocedural anticoagulation therapy for devices and atrial fibrillation ablation. <i>Europace</i> , 2012 , 14, 741-4	3.9	14
265	A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study. <i>Chest</i> , 2012 , 141, 339-347	5.3	91
264	Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2012 , 30, 239-52	1.9	138
263	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 1009-22	7	49

262	Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. <i>Europace</i> , 2012 , 14, 1553-9	3.9	117
261	Anticoagulation in Atrial Fibrillation. <i>Arrhythmia and Electrophysiology Review</i> , 2012 , 1, 12-16	3.2	2
260	Preventative Measures of Stroke in Patients With Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2012 , 4, 399	0.8	2
259	What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation?. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2012 , 42 Suppl 18, 35-44	0.9	5
258	Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 173-80	15.1	721
257	Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 1339-48	15.1	156
256	Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 2496-504	15.1	105
255	Comparative Analysis of the HAS-BLED Score With Other Bleeding Risk Scores, Using Estimates of Net Reclassification Improvement and Integrated Discrimination Improvement. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 1398-1399	15.1	3
254	Antiplatelet agents and anticoagulants for hypertension. <i>The Cochrane Library</i> , 2011 , CD003186	5.2	13
253	Apixaban in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 364, 806-17	59.2	1772
252	Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. <i>BMJ, The</i> , 2011 , 342, d124	5.9	913
251	Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 739-49	7	332
250	Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. <i>American Journal of Medicine</i> , 2011 , 124, 111-4	2.4	105
249	Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. <i>Thrombosis Research</i> , 2011 , 127, 81-9	8.2	25
248	The quest for new anticoagulants: from clinical development to clinical practice. <i>Cardiovascular Therapeutics</i> , 2011 , 29, e12-22	3.3	8
247	The Improved but Unfinished Business of Stroke Risk Stratification in Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011 , 64, 639-641	0.7	
246	Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 997-1011	7	184
245	Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation. <i>Chest</i> , 2011 , 140, 918-924	5.3	24

244	New anticoagulation drugs for atrial fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 90, 502-6	6.1	5
243	Endothelium-dependent and endothelium-independent vasodilatation of the cutaneous circulation in sickle cell disease. <i>European Journal of Clinical Investigation</i> , 2011 , 41, 546-51	4.6	12
242	A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 39-48	15.4	193
241	Intracardiac expression of markers of endothelial damage/dysfunction, inflammation, thrombosis, and tissue remodeling, and the development of postoperative atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 2345-52	15.4	28
240	Peri-operative management of ophthalmic patients taking antithrombotic therapy. <i>International Journal of Clinical Practice</i> , 2011 , 65, 361-71	2.9	13
239	Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9 Suppl 1, 344-51	15.4	67
238	Assessment of left atrial volume: a focus on echocardiographic methods and clinical implications. <i>Clinical Research in Cardiology</i> , 2011 , 100, 97-105	6.1	24
237	Endothelial dysfunction in hypertension in pregnancy: associations between circulating endothelial cells, circulating progenitor cells and plasma von Willebrand factor. <i>Clinical Research in Cardiology</i> , 2011 , 100, 531-7	6.1	23
236	What is the role of the cardiologist in future management of stroke prevention in atrial fibrillation?. <i>Advances in Therapy</i> , 2011 , 28, 1-12	4.1	3
235	Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a comparison with plasma vascular markers. <i>Prostate</i> , 2011 , 71, 1047-53	4.2	18
234	Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study. <i>European Journal of Heart Failure</i> , 2011 , 13, 489-95	12.3	17
233	The role of aspirin for stroke prevention in atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2011 , 8, 602-6	14.8	81
232	Dronedronarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 131-40	4	12
231	The role of monocytes and inflammation in the pathophysiology of heart failure. <i>European Journal of Heart Failure</i> , 2011 , 13, 1161-71	12.3	126
230	Persistent macrovascular and microvascular dysfunction in patients with malignant hypertension. <i>Hypertension</i> , 2011 , 57, 490-6	8.5	35
229	Myocardial perfusion by myocardial contrast echocardiography and endothelial dysfunction in obstructive sleep apnea. <i>Hypertension</i> , 2011 , 58, 417-24	8.5	46
228	Impact of polymorphisms in the renin-angiotensin-aldosterone system on hypertrophic cardiomyopathy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2011 , 12, 521-30	3	16
227	An evaluation of the CHADS ₂ stroke risk score in patients with atrial fibrillation who undergo percutaneous coronary revascularization. <i>Chest</i> , 2011 , 139, 1402-1409	5.3	12

226	Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. <i>Chest</i> , 2011 , 140, 911-917	5.3	63
225	Chronic renal disease and stroke in atrial fibrillation: balancing the prevention of thromboembolism and bleeding risk. <i>Europace</i> , 2011 , 13, 145-8	3.9	22
224	Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. <i>Stroke</i> , 2011 , 42, 1768-70	6.7	148
223	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011 , 13, 723-46	3.9	166
222	Nebivolol for the treatment of heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 1733-46	5.9	7
221	Lone atrial fibrillation: where are we now?. <i>Hospital Practice (1995)</i> , 2011 , 39, 17-31	2.2	7
220	Atrial fibrillation in 2011: Stroke prevention in AF. <i>Nature Reviews Cardiology</i> , 2011 , 9, 71-3	14.8	12
219	Atrial fibrillation (acute onset). <i>Clinical Evidence</i> , 2011 , 2011,		1
218	Recent progress in antithrombotic therapy for atrial fibrillation. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011 , 18, 257-73	4	3
217	The impact of new and emerging clinical data on treatment strategies for atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2010 , 21, 946-58	2.7	19
216	Peripheral artery disease: appreciating the asymptomatic - yet lethal - epidemic. <i>International Journal of Clinical Practice</i> , 2010 , 64, 832-5	2.9	1
215	Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 683-5	7	58
214	Dabigatran and warfarin in vitamin K antagonist-naïve and -experienced cohorts with atrial fibrillation. <i>Circulation</i> , 2010 , 122, 2246-53	16.7	138
213	Simplifying stroke risk stratification in atrial fibrillation patients: implications of the CHA2DS2-VASc risk stratification scores. <i>Age and Ageing</i> , 2010 , 39, 533-5	3	36
212	Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 685-7	4	18
211	The assessment of stroke and bleeding risk in atrial fibrillation: where are we now?. <i>Expert Review of Cardiovascular Therapy</i> , 2010 , 8, 1703-10	2.5	2
210	Assessment of endothelial dysfunction. <i>Expert Review of Cardiovascular Therapy</i> , 2010 , 8, 557-71	2.5	14
209	Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2010 , 31, 1311-8	9.5	179

208	Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. <i>Annals of Medicine</i> , 2010 , 42, 562-75	1.5	10
207	Apolipoproteins in the discrimination of atherosclerotic burden and cardiac function in patients with stable coronary artery disease. <i>European Journal of Heart Failure</i> , 2010 , 12, 254-9	12.3	5
206	Impact of symptom control on health-related quality of life in atrial fibrillation patients: the psychologist's viewpoint. <i>Europace</i> , 2010 , 12, 608-10	3.9	9
205	Guidelines for antithrombotic therapy in atrial fibrillation: understanding the reasons for non-adherence and moving forwards with simplifying risk stratification for stroke and bleeding. <i>Europace</i> , 2010 , 12, 761-3	3.9	8
204	Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. <i>Stroke</i> , 2010 , 41, 2731-8	6.7	368
203	Stroke prevention in atrial fibrillation patients. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2331-50	4	4
202	Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 827-37	15.1	168
201	Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 2067-76	15.1	53
200	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 13-28	7	232
199	Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2010 , 31, 2369-429	9.5	3452
198	Improving stroke risk stratification in atrial fibrillation. <i>American Journal of Medicine</i> , 2010 , 123, 484-8	2.4	144
197	A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. <i>Chest</i> , 2010 , 138, 1093-100	5.3	2947
196	Plasma YKL-40 levels are elevated in patients with chronic heart failure. <i>Scandinavian Cardiovascular Journal</i> , 2010 , 44, 92-9	2	22
195	Towards (cost)effective cardiovascular risk management: using new drugs vs. the better use of available ones. <i>International Journal of Clinical Practice</i> , 2010 , 64, 138-40	2.9	2
194	Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. <i>Chest</i> , 2010 , 137, 263-72	5.3	4353
193	Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 1106-15	7	90
192	Soluble fms-like tyrosine kinase-1 is a novel marker for atherosclerotic progression? <i>Circulation Journal</i> , 2010 , 74, 2064-5	2.9	2
191	Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk. <i>Lancet Neurology</i> , 2010 , 9, 1140-1142	24.1	8

190	TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). <i>BMC Cardiovascular Disorders</i> , 2010 , 10, 21	2.3	25
189	Endothelial progenitor cells: what use for the cardiologist?. <i>Journal of Angiogenesis Research</i> , 2010 , 2, 6		32
188	Antithrombotic therapy: what the dental surgeon has to know. <i>Faculty Dental Journal</i> , 2010 , 1, 92-98	0.6	
187	Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation". <i>Thrombosis and Haemostasis</i> , 2009 , 102, 914-5	7	11
186	Vernakalant hydrochloride for the treatment of atrial fibrillation. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1929-37	5.9	10
185	Clinical outcomes of acute stroke patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 371-4	2.5	26
184	Impaired glucose tolerance and endothelial damage, as assessed by levels of von Willebrand factor and circulating endothelial cells, following acute myocardial infarction. <i>Annals of Medicine</i> , 2009 , 41, 608-18	1.5	6
183	How safe is the antiarrhythmic drug therapy in atrial fibrillation?. <i>Europace</i> , 2009 , 11, 837-9	3.9	1
182	Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 473-81	2.5	7
181	Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. <i>European Heart Journal</i> , 2009 , 30, 2897-907	9.5	77
180	Balancing thromboembolism and bleeding risks: insights from anticoagulation for prosthetic heart valves. <i>Chest</i> , 2009 , 136, 1451-1452	5.3	1
179	Acute management of atrial fibrillation. <i>Chest</i> , 2009 , 135, 849-859	5.3	37
178	Quality of life in older people with atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2009 , 25, 37-42	2.4	30
177	Renin-angiotensin-aldosterone system blockade in atrial fibrillation and left atrial remodelling. <i>International Journal of Clinical Practice</i> , 2009 , 63, 982-5	2.9	2
176	Antithrombotic therapy for heart failure in sinus rhythm. <i>Fundamental and Clinical Pharmacology</i> , 2009 , 23, 705-17	3.1	8
175	Assessment of endothelial (dys)function in atrial fibrillation. <i>Annals of Medicine</i> , 2009 , 41, 576-90	1.5	16
174	Influence of electrical cardioversion on inflammation and indexes of structural remodeling, in persistent atrial fibrillation. <i>International Journal of Cardiology</i> , 2009 , 132, 227-32	3.2	10
173	Response to the letter by Dr Jolobe: Risk factors and stroke risk stratification for atrial fibrillation: Limitations and new possibilities. <i>American Heart Journal</i> , 2009 , 157, e7	4.9	

172	Hypertension to heart failure: a pathophysiological spectrum relating blood pressure, drug treatments and stroke. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 703-13	2.5	15
171	Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1191-6	5.9	3
170	Fondaparinux: an overview. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 577-85	2.5	11
169	Burden of atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2009 , 25, 1261-3	2.5	10
168	New anticoagulants for the prevention of deep venous thrombosis: time to consider cost effectiveness?. <i>Pharmacoeconomics</i> , 2009 , 27, 793-5	4.4	1
167	Circulating levels of adiponectin, leptin, and tumour necrosis factor alpha in hypertension. <i>Annals of Medicine</i> , 2009 , 41, 291-300	1.5	18
166	Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. <i>Lancet, The</i> , 2009 , 373, 155-66	4.0	655
165	Performing repeated noninvasive bedside measures of volume response to intravenous furosemide in acute pulmonary edema: a feasibility assessment. <i>Cardiovascular Therapeutics</i> , 2009 , 27, 89-95	3.3	13
164	Impact of chronic kidney disease on major bleeding complications and mortality in patients with indication for oral anticoagulation undergoing coronary stenting. <i>Chest</i> , 2009 , 135, 983-990	5.3	17
163	Thrombosis prophylaxis in patients with ischaemic (cardioembolic) stroke. How long is long enough?. <i>Hamostaseologie</i> , 2009 , 29, 96-101	1.9	
162	Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. <i>Journal of Internal Medicine</i> , 2008 , 264, 50-61	10.8	47
161	Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 818-25	15.1	206
160	The role of aspirin in cardiovascular prevention: implications of aspirin resistance. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 1829-43	15.1	218
159	Hemoxygenase-1 in cardiovascular disease. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 971-8	5.1	109
158	Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels. <i>Thrombosis Research</i> , 2008 , 122, 85-90	8.2	64
157	Vital exhaustion and cardiovascular disease: are circulating fibrinogen and D-dimer levels a plausible link?. <i>Stress</i> , 2008 , 11, 247-9	3	2
156	The endothelium, arterial stiffness, and von Willebrand factor levels in hypertensive women: effects of ethnicity. <i>American Journal of Hypertension</i> , 2008 , 21, 1275-6	2.3	1
155	Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. <i>Chest</i> , 2008 , 134, 559-567	5.3	102

154	Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. <i>BMJ, The</i> , 2008 , 336, 614-5	5.9	34
153	Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation: relationship to soluble P-selectin, stroke risk factors, and risk factor intervention. <i>Chest</i> , 2008 , 134, 574-581	5.3	32
152	Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?. <i>European Heart Journal</i> , 2008 , 29, 915-22	9.5	90
151	Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis. <i>Thrombosis and Haemostasis</i> , 2008 , 100, 11-3	7	29
150	The effects of coronary artery disease severity on time-dependent changes in platelet activation indices in stored whole blood. <i>Journal of Thrombosis and Thrombolysis</i> , 2008 , 25, 135-40	5.1	29
149	New approaches to therapy with omega-3 fatty acids. <i>Current Atherosclerosis Reports</i> , 2008 , 10, 79-87	6	12
148	Antithrombotic therapy use after percutaneous coronary intervention and stent implantation in patients taking chronic oral anticoagulation. <i>JACC: Cardiovascular Interventions</i> , 2008 , 1, 329; author reply 330-1	5	1
147	Managing the anticoagulated patient with atrial fibrillation at high risk of stroke who needs coronary intervention. <i>BMJ, The</i> , 2008 , 337, a840	5.9	3
146	Hypertension: endothelial dysfunction, the prothrombotic state and antithrombotic therapy. <i>Expert Review of Cardiovascular Therapy</i> , 2007 , 5, 441-50	2.5	15
145	Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation. <i>Journal of Internal Medicine</i> , 2007 , 261, 577-86	10.8	10
144	Stroke prevention in atrial fibrillation--things can only get better. <i>British Journal of Clinical Pharmacology</i> , 2007 , 64, 575-7	3.8	3
143	Is it the post-challenge hyperglycaemic spike or arterial stiffness we should be screening for?. <i>International Journal of Clinical Practice</i> , 2007 , 61, 356-8	2.9	
142	Atrial fibrillation and stroke prevention. <i>Lancet Neurology, The</i> , 2007 , 6, 981-93	24.1	174
141	Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. <i>BMJ, The</i> , 2007 , 335, 383	5.9	257
140	Effects of low osmolar contrast (iomeprol) on haemorheology and platelet activation in patients with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2007 , 23, 189-94	5.1	4
139	Atherosclerotic renal artery stenosis--do we really know what to do?. <i>Blood Pressure</i> , 2007 , 16, 288-90	1.7	
138	Coronary sinus blood sampling: an insight into local cardiac pathophysiology and treatment?. <i>European Heart Journal</i> , 2007 , 28, 929-40	9.5	17
137	Peripheral artery disease and hypertension: the relation between ankle-brachial index and mortality. <i>Journal of Human Hypertension</i> , 2007 , 21, 762-5	2.6	4

136	Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. <i>BMJ, The</i> , 2007 , 335, 380	5.9	97
135	Viewpoint: the prothrombotic state in heart failure: a maladaptive inflammatory response?. <i>European Journal of Heart Failure</i> , 2007 , 9, 124-8	12.3	25
134	Effect of hypertension on anticoagulated patients with atrial fibrillation. <i>European Heart Journal</i> , 2007 , 28, 752-9	9.5	111
133	Relationship between circulating endothelial cells and the predicted risk of cardiovascular events in acute coronary syndromes. <i>European Heart Journal</i> , 2007 , 28, 1092-101	9.5	35
132	Stroke prevention in atrial fibrillation: antiplatelet therapy revisited. <i>European Heart Journal</i> , 2007 , 28, 926-8	9.5	3
131	Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2007 , 100, 599-607	2.7	171
130	High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. <i>Stroke</i> , 2007 , 38, 1229-37	6.7	146
129	Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. <i>Journal of Human Hypertension</i> , 2007 , 21, 183-211	2.6	94
128	Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. <i>Europace</i> , 2007 , 9, 1006-23	3.9	197
127	Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 1235-43	4	4
126	The new NICE guideline on atrial fibrillation management. <i>Heart</i> , 2007 , 93, 23	5.1	7
125	Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy. <i>Chest</i> , 2007 , 131, 809-815	5.3	93
124	Platelet adhesion in atrial fibrillation. <i>Thrombosis Research</i> , 2007 , 120, 623-9	8.2	8
123	Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. <i>American Heart Journal</i> , 2007 , 153, 1006-12	4.9	170
122	Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. <i>Lancet, The</i> , 2007 , 370, 493-503	40	1175
121	Management of atrial fibrillation. <i>Lancet, The</i> , 2007 , 370, 604-18	40	164
120	Antithrombotic treatment in atrial fibrillation. <i>Postgraduate Medical Journal</i> , 2006 , 92, 155-61	2	31
119	Management of atrial fibrillation. <i>Herz</i> , 2006 , 31, 849-56	2.6	0

118	Platelet microparticles and platelet adhesion: therapeutic implications for the prevention and treatment of stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2006 , 8, 251-8	2.1	6
117	Antithrombotic therapy: standard therapy in essential hypertension?. <i>Progress in Cardiovascular Diseases</i> , 2006 , 49, 11-5	8.5	4
116	Target organ damage in hypertension: pathophysiology and implications for drug therapy. <i>Current Pharmaceutical Design</i> , 2006 , 12, 1581-92	3.3	54
115	Management of atrial fibrillation. <i>Heart</i> , 2006 , 92, 1177-82	5.1	63
114	Blood pressure control and prevention of stroke. <i>Expert Review of Neurotherapeutics</i> , 2006 , 6, 203-12	4.3	
113	Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. <i>European Heart Journal</i> , 2006 , 27, 949-53	9.5	1299
112	Anticoagulation for stroke prevention: high effectiveness, more cost benefit?. <i>Pharmacoeconomics</i> , 2006 , 24, 1035-8	4.4	
111	Atrial fibrillation and stroke prevention. <i>Expert Review of Neurotherapeutics</i> , 2006 , 6, 1523-30	4.3	3
110	Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. <i>Chest</i> , 2006 , 130, 1823-7	5.3	70
109	Atrial fibrillation post-cardiac surgery: changing perspectives. <i>Current Medical Research and Opinion</i> , 2006 , 22, 1437-41	2.5	36
108	Quality of life in patients with atrial fibrillation: a systematic review. <i>American Journal of Medicine</i> , 2006 , 119, 448.e1-19	2.4	372
107	Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , 2006 , 110, 354-8	3.2	124
106	Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. <i>Thrombosis Research</i> , 2006 , 118, 321-33	8.2	174
105	Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: a methodological comparison. <i>Thrombosis and Haemostasis</i> , 2006 , 96, 45-52	7	86
104	Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. <i>Stroke</i> , 2006 , 37, 2294-300	6.7	119
103	Aortic elasticity, left ventricular geometry and diastolic dysfunction in hypertension. <i>International Journal of Clinical Practice</i> , 2006 , 60, 1337-40	2.9	
102	The endothelium, inflammation, and coagulation in sepsis. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, 20-2	6.1	15
101	Temporal and venepuncture-related decline in circulating endothelial cell capture from mixed venous blood. <i>Journal of Thrombosis and Thrombolysis</i> , 2006 , 22, 125-31	5.1	13

100	Antithrombotic therapy for congestive heart failure. <i>International Journal of Clinical Practice</i> , 2006 , 60, 36-47	2.9	9
99	Preventing stroke in atrial fibrillation: the SPORTIF programme. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2005 , 34 Suppl 1, 25-30		8
98	Rheumatoid disease and the heart: from epidemiology to echocardiography. <i>Expert Opinion on Investigational Drugs</i> , 2005 , 14, 65-76	5.9	3
97	New evidence of anti-inflammatory interventions in atrial fibrillation: reply. <i>European Heart Journal</i> , 2005 , 27, 501-501	9.5	
96	Targeting the renin-angiotensin-aldosterone-system in atrial fibrillation: a shift from electrical to structural therapy?. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 2193-207	4	17
95	Endothelial function and its assessment. <i>Expert Opinion on Investigational Drugs</i> , 2005 , 14, 1319-36	5.9	26
94	Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. <i>Annals of Medicine</i> , 2005 , 37, 61-6	1.5	85
93	Ximelagatran for stroke prevention in atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2005 , 3, 551-63	2.5	3
92	Platelet adhesion in hypertension: application of a novel assay of platelet adhesion. <i>Annals of Medicine</i> , 2005 , 37, 55-60	1.5	9
91	The effect of multi-factorial intervention on plasma von Willebrand factor, soluble E-selectin and tissue factor in diabetes mellitus: implications for atherosclerotic vascular disease. <i>Diabetic Medicine</i> , 2005 , 22, 249-55	3.5	14
90	Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels. <i>Diabetic Medicine</i> , 2005 , 22, 1657-62	3.5	68
89	Type 2 diabetes mellitus: a cardiovascular perspective. <i>International Journal of Clinical Practice</i> , 2005 , 59, 798-816	2.9	38
88	Tissue inhibitor of metalloproteinase-1 is a marker of diastolic dysfunction using tissue doppler in patients with type 2 diabetes and hypertension. <i>European Journal of Clinical Investigation</i> , 2005 , 35, 8-12	4.6	28
87	Is hypertension a prothrombotic state?. <i>Current Hypertension Reports</i> , 2005 , 7, 168-73	4.7	27
86	Biomarkers in atrial fibrillation: further observations on biologic plausibility, cause and effect. <i>Journal of Thrombosis and Thrombolysis</i> , 2005 , 20, 189-90	5.1	1
85	Hormone replacement therapy and arterial blood pressure in postmenopausal women with hypertension. <i>Blood Pressure</i> , 2005 , 14, 38-44	1.7	12
84	Ambulatory blood pressure monitoring in heart failure: a systematic review. <i>European Journal of Heart Failure</i> , 2005 , 7, 149-56	12.3	20
83	Hibernating myocardium in heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2005 , 3, 111-22	2.5	7

82	Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation. <i>Heart</i> , 2005 , 91, 759-63	5.1	32
81	Inflammation, arrhythmia burden and the thrombotic consequences of atrial fibrillation. <i>European Heart Journal</i> , 2004 , 25, 1761	9.5	8
80	Endothelial dysfunction: methods of assessment and application to hypertension. <i>Current Pharmaceutical Design</i> , 2004 , 10, 3591-605	3.3	88
79	Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. <i>British Journal of Ophthalmology</i> , 2004 , 88, 1543-6	5.5	44
78	Ethnic differences in patient perceptions of heart failure and treatment: the West Birmingham heart failure project. <i>Heart</i> , 2004 , 90, 1016-9	5.1	30
77	Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. <i>Heart</i> , 2004 , 90, 1162-6	5.1	65
76	Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. <i>Annals of Medicine</i> , 2004 , 36, 552-7	1.5	99
75	Platelet activation in the hypertensive disorders of pregnancy. <i>Expert Opinion on Investigational Drugs</i> , 2004 , 13, 523-9	5.9	11
74	Heart failure--the importance of ethnicity. <i>European Journal of Heart Failure</i> , 2004 , 6, 831-43	12.3	19
73	An 8-year follow-up study of acute admissions with heart failure in a multiethnic population. <i>European Journal of Heart Failure</i> , 2004 , 6, 669-72	12.3	12
72	Left ventricular systolic dysfunction and atrial fibrillation in older people in the community: the need for identification, as well as appropriate management. <i>Age and Ageing</i> , 2004 , 33, 434-6	3	1
71	Autonomic reflexes in heterotopic heart transplantation. <i>International Journal of Clinical Practice</i> , 2004 , 58, 520-2	2.9	
70	Angiopoietin/tie-2 as mediators of angiogenesis: a role in congestive heart failure?. <i>European Journal of Clinical Investigation</i> , 2004 , 34, 9-13	4.6	22
69	Effects of dietary fat intake in sudden death: reduction of death with omega-3 fatty acids. <i>Current Cardiology Reports</i> , 2004 , 6, 371-8	4.2	8
68	Atrial fibrillation post-myocardial infarction: frequency, consequences, and management. <i>Current Heart Failure Reports</i> , 2004 , 1, 149-55	2.8	8
67	Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. <i>Blood Pressure</i> , 2004 , 13, 183-9	1.7	27
66	Tedisamil: a new novel antiarrhythmic. <i>Expert Opinion on Investigational Drugs</i> , 2004 , 13, 151-60	5.9	9
65	Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility. <i>Expert Opinion on Investigational Drugs</i> , 2004 , 13, 841-55	5.9	11

64	Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension: Relationship to tissue Doppler indices of diastolic relaxation. <i>American Journal of Hypertension</i> , 2004 , 17, 770-774	2.3	37
63	Matrix metalloproteinases in atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 152; author reply 152-3	15.1	
62	Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 2075-82	15.1	215
61	Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). <i>Journal of the American College of Cardiology</i> , 2004 , 44, 415-22	15.1	128
60	Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. <i>American Heart Journal</i> , 2004 , 148, 462-6	4.9	169
59	Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). <i>American Journal of Hypertension</i> , 2004 , 17, 764-9	2.3	64
58	Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation. <i>American Journal of Hypertension</i> , 2004 , 17, 770-4	2.3	41
57	Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. <i>Annals of Medicine</i> , 2004 , 36, 273-7	1.5	52
56	Dual chamber versus single chamber ventricular pacemakers for sick sinus syndrome and atrioventricular block. <i>The Cochrane Library</i> , 2004 , CD003710	5.2	32
55	Thrombogenesis, atherogenesis and angiogenesis in vascular disease: a new 'vascular triad'. <i>Annals of Medicine</i> , 2004 , 36, 119-25	1.5	41
54	Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?. <i>Stroke</i> , 2003 , 34, 1181-6	6.7	80
53	Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure. <i>European Journal of Heart Failure</i> , 2003 , 5, 171-4	12.3	34
52	Heart failure in a multiethnic population in Kuala Lumpur, Malaysia. <i>European Journal of Heart Failure</i> , 2003 , 5, 569-74	12.3	34
51	Psychosocial functioning of adults with congenital heart disease: a neglected area. <i>European Heart Journal</i> , 2003 , 24, 2159; author reply 2159-60	9.5	2
50	Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study. <i>Stroke</i> , 2003 , 34, 413-8.	7.7	81
49	Ethnicity and arrhythmias. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003 , 7, 92-5		5
48	Congestive heart failure and Virchow's triad: a neglected association. <i>Wiener Medizinische Wochenschrift</i> , 2003 , 153, 411-6	2.9	7
47	Atrial fibrillation: should we target platelets or the coagulation pathway?. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003 , 7, 370-1		7

46	Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). <i>American Journal of Cardiology</i> , 2003 , 92, 400-5	3	85
45	Coagulopathic complications in breast cancer. <i>Cancer</i> , 2003 , 98, 1578-86	6.4	59
44	Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay. <i>European Journal of Clinical Investigation</i> , 2003 , 33, 529-35	4.6	33
43	Basic fibroblast growth factor induces the secretion of vascular endothelial growth factor by human aortic smooth muscle cells but not by endothelial cells. <i>European Journal of Clinical Investigation</i> , 2003 , 33, 833-9	4.6	28
42	Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. <i>European Journal of Clinical Investigation</i> , 2003 , 33, 883-90	4.6	72
41	Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. <i>European Journal of Clinical Investigation</i> , 2003 , 33, 941-8	4.6	64
40	More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2). <i>Journal of Human Hypertension</i> , 2003 , 17, 747-50	2.6	20
39	Platelets, atherosclerosis and the endothelium: new therapeutic targets?. <i>Expert Opinion on Investigational Drugs</i> , 2003 , 12, 1765-76	5.9	12
38	Factor X inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2003 , 12, 799-804	5.9	7
37	Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. <i>Circulation</i> , 2003 , 107, 3141-5	16.7	226
36	Alcohol and cardiovascular disease--more than one paradox to consider. Alcohol and hypertension--does it matter? (no!). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003 , 10, 11-4		4
35	Vascular endothelial growth factor and soluble P-selectin in acute and chronic congestive heart failure. <i>American Journal of Cardiology</i> , 2002 , 90, 1258-60	3	52
34	Hypertension, left ventricular hypertrophy, and sudden death. <i>Current Cardiology Reports</i> , 2002 , 4, 449-57	4.2	41
33	Anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2002 , 95, 451-9	2.7	20
32	Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2002 , 95, 461-8	2.7	21
31	Ongoing trials involving angiotensin-converting enzyme inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2002 , 11, 1633-43	5.9	1
30	Oxidative stress in malignant and non-malignant phase hypertension. <i>Journal of Human Hypertension</i> , 2002 , 16, 333-6	2.6	65
29	Airborne occupational exposure and ABO phenotype: an example of gene-environment interaction in ischaemic heart disease?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2002 , 9, 179-82		

28	Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project. <i>Blood Coagulation and Fibrinolysis</i> , 2002 , 13, 339-47	1	59
27	Baseline abnormalities of endothelial function and thrombogenesis in relation to prognosis in essential hypertension. <i>Blood Coagulation and Fibrinolysis</i> , 2002 , 13, 35-41	1	19
26	Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project. <i>Stroke</i> , 2002 , 33, 238-42	6.7	129
25	Hormone replacement therapy and cardiovascular risk. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2002 , 1, 95-103		3
24	Cancer and the prothrombotic state. <i>Lancet Oncology, The</i> , 2002 , 3, 27-34	21.7	281
23	Abnormal haemorheology, endothelial function and thrombogenesis in relation to hypertension in acute (ictus) Blood Coagulation and Fibrinolysis, 2001 , 12, 307-15	1	19
22	Resistant hypertension and the Birmingham Hypertension Square. <i>Current Hypertension Reports</i> , 2001 , 3, 203-8	4.7	5
21	Calcium antagonists in diabetic hypertension. <i>Diabetes, Obesity and Metabolism</i> , 2001 , 3, 311-8	6.7	0
20	Anticoagulation for heart failure in sinus rhythm. <i>Cochrane Database of Systematic Reviews</i> , 2001 , CD003336		3
19	Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm. <i>Cochrane Database of Systematic Reviews</i> , 2001 , CD003333		8
18	Diurnal rhythms and hemostatic factors in atrial fibrillation: reply. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 970-971	15.1	1
17	Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 2133-5	15.1	1
16	A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension. <i>American Journal of Hypertension</i> , 2001 , 14, 823-8	2.3	31
15	Management of hypertension in pregnancy. <i>American Journal of Cardiovascular Drugs</i> , 2001 , 1, 253-62	4	10
14	Serum urate is associated with baseline renal dysfunction but not survival or deterioration in renal function in malignant phase hypertension. <i>Journal of Hypertension</i> , 2000 , 18, 97-101	1.9	8
13	A pilot study of streptokinase-induced endothelial injury and platelet activation following acute myocardial infarction. <i>Journal of Internal Medicine</i> , 2000 , 248, 316-8	10.8	9
12	Do patients with de novo hypertension differ from patients with previously known hypertension when malignant phase hypertension occurs?. <i>American Journal of Hypertension</i> , 2000 , 13, 934-9	2.3	8
11	A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 1926-31	15.1	84

10	Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. <i>Stroke</i> , 1999 , 30, 2547-53	6.7	129
9	Endothelial integrity, soluble adhesion molecules and platelet markers in Type 1 diabetes mellitus. <i>Diabetic Medicine</i> , 1999 , 16, 86-7	3.5	2
8	Prothrombotic factors, endothelial function and left ventricular hypertrophy in isolated systolic hypertension compared with systolic-diastolic hypertension. <i>Journal of Hypertension</i> , 1999 , 17, 1203-7	1.9	26
7	Antihypertensive drug treatment and fibrinolytic function. <i>American Journal of Hypertension</i> , 1998 , 11, 1266-7	2.3	2
6	Measurement of Diastolic Blood Pressure in Obstetrical Research. <i>Hypertension in Pregnancy</i> , 1996 , 15, 135-137	2	3
5	Alcohol, hypertension, coronary disease and stroke. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1995 , 22, 189-94	3	27
4	Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. <i>International Journal of Cardiology</i> , 1995 , 51, 245-51	3.2	62
3	Left Atrial Appendage Morphology Impacts Thrombus Formation Risks in Multi-Physics Atrial Models		0
2	Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials		3
1	Artificial intelligence to detect abnormal heart rhythm from scanned electrocardiogram tracings. <i>Journal of Arrhythmia</i> ,	1.5	1